<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002474</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>776</s160></s100><s200><s210>1</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 1Met Ile Pro Thr Phe Thr Ala Leu Leu1               5</s400><s200><s210>2</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 2Thr Leu Leu Lys Ala Leu Leu Glu Ile1               5</s400><s200><s210>3</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 3Ala Leu Ile Tyr Asn Leu Val Gly Ile1               5</s400><s200><s210>4</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 4Ala Leu Phe Lys Ala Trp Ala Leu1               5</s400><s200><s210>5</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 5Arg Leu Leu Asp Phe Ile Asn Val Leu1               5</s400><s200><s210>6</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 6Ser Leu Gly Lys His Thr Val Ala Leu1               5</s400><s200><s210>7</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 7Ala Leu Gln Ala Phe Glu Phe Arg Val1               5</s400><s200><s210>8</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 8Tyr Leu Val Thr Lys Val Val Ala Val1               5</s400><s200><s210>9</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 9Val Leu Leu Ala Gly Phe Lys Pro Pro Leu1               5                   10</s400><s200><s210>10</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 10Arg Tyr Ser Asp Ser Val Gly Arg Val Ser Phe1               5                   10</s400><s200><s210>11</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 11Ser Tyr Ser Asp Leu His Tyr Gly Phe1               5</s400><s200><s210>12</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 12Lys Tyr Glu Lys Ile Phe Glu Met Leu1               5</s400><s200><s210>13</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 13Val Tyr Thr Phe Leu Ser Ser Thr Leu1               5</s400><s200><s210>14</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 14Phe Tyr Phe Pro Thr Pro Thr Val Leu1               5</s400><s200><s210>15</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 15Val Tyr His Asp Asp Lys Gln Pro Thr Phe1               5                   10</s400><s200><s210>16</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 16Ile Tyr Ser Pro Gln Phe Ser Arg Leu1               5</s400><s200><s210>17</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 17Arg Phe Thr Thr Met Leu Ser Thr Phe1               5</s400><s200><s210>18</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 18Lys Tyr Pro Val His Ile Tyr Arg Leu1               5</s400><s200><s210>19</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 19Lys Tyr Val Lys Val Phe His Gln Phe1               5</s400><s200><s210>20</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 20Arg Met Ala Ser Pro Val Asn Val Lys1               5</s400><s200><s210>21</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 21Ala Val Arg Lys Pro Ile Val Leu Lys1               5</s400><s200><s210>22</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 22Ser Leu Lys Glu Arg Asn Pro Leu Lys1               5</s400><s200><s210>23</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 23Gly Met Met Lys Gly Gly Ile Arg Lys1               5</s400><s200><s210>24</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 24Ser Met Tyr Tyr Pro Leu Gln Leu Lys1               5</s400><s200><s210>25</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 25Gly Thr Ser Pro Pro Ser Val Glu Lys1               5</s400><s200><s210>26</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 26Arg Ile Ser Glu Tyr Leu Leu Glu Lys1               5</s400><s200><s210>27</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 27Val Leu Tyr Gly Pro Ala Gly Leu Gly Lys1               5                   10</s400><s200><s210>28</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 28Lys Thr Tyr Glu Thr Asn Leu Glu Ile Lys Lys1               5                   10</s400><s200><s210>29</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 29Gln Gln Phe Leu Thr Ala Leu Phe Tyr1               5</s400><s200><s210>30</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 30Ala Leu Glu Val Ala His Arg Leu Lys1               5</s400><s200><s210>31</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 31Leu Leu Asp Glu Gly Ala Met Leu Leu Tyr1               5                   10</s400><s200><s210>32</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 32Ser Pro Asn Lys Gly Thr Leu Ser Val1               5</s400><s200><s210>33</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 33Ser Pro Thr Phe His Leu Thr Leu1               5</s400><s200><s210>34</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 34Leu Pro Arg Gly Pro Leu Ala Ser Leu Leu1               5                   10</s400><s200><s210>35</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 35Phe Pro Asp Asn Gln Arg Pro Ala Leu1               5</s400><s200><s210>36</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 36Ala Pro Ala Ala Trp Leu Arg Ser Ala1               5</s400><s200><s210>37</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 37Arg Pro Leu Phe Gln Lys Ser Ser Met1               5</s400><s200><s210>38</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 38Ser Pro His Pro Val Thr Ala Leu Leu Thr Leu1               5                   10</s400><s200><s210>39</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 39Arg Pro Ala Pro Phe Glu Val Val Phe1               5</s400><s200><s210>40</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 40Lys Pro Gly Thr Ser Tyr Arg Val Thr Leu1               5                   10</s400><s200><s210>41</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 41Arg Val Arg Ser Arg Ile Ser Asn Leu1               5</s400><s200><s210>42</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 42Thr Leu Lys Val Thr Ser Ala Leu1               5</s400><s200><s210>43</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 43Ala Leu Lys Ala Arg Thr Val Thr Phe1               5</s400><s200><s210>44</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 44Leu Asn Lys Gln Lys Val Thr Phe1               5</s400><s200><s210>45</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 45Val Gly Arg Glu Lys Lys Leu Ala Leu1               5</s400><s200><s210>46</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 46Asp Met Lys Lys Ala Lys Glu Gln Leu1               5</s400><s200><s210>47</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 47Met Pro Asn Leu Arg Ser Val Asp Leu1               5</s400><s200><s210>48</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 48Asp Val Lys Lys Lys Ile Lys Glu Val1               5</s400><s200><s210>49</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 49Leu Pro Arg Leu Lys Ala Phe Met Ile1               5</s400><s200><s210>50</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 50Asp Met Lys Tyr Lys Asn Arg Val1               5</s400><s200><s210>51</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 51Ser Leu Arg Leu Lys Asn Val Gln Leu1               5</s400><s200><s210>52</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 52Ala Glu Phe Leu Leu Arg Ile Phe Leu1               5</s400><s200><s210>53</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 53Met Glu His Pro Gly Lys Leu Leu Phe1               5</s400><s200><s210>54</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 54Ala Glu Ile Thr Ile Thr Thr Gln Thr Gly Tyr1               5                   10</s400><s200><s210>55</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 55His Glu Thr Glu Thr Arg Thr Thr Trp1               5</s400><s200><s210>56</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 56Ser Glu Pro Asp Thr Thr Ala Ser Trp1               5</s400><s200><s210>57</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 57Gln Glu Ser Asp Leu Arg Leu Phe Leu1               5</s400><s200><s210>58</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 58Gly Glu Met Glu Gln Lys Gln Leu1               5</s400><s200><s210>59</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 59Ser Glu Asn Val Thr Met Lys Val Val1               5</s400><s200><s210>60</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 60Gly Leu Leu Ser Leu Thr Ser Thr Leu Tyr Leu1               5                   10</s400><s200><s210>61</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 61Tyr Met Val His Ile Gln Val Thr Leu1               5</s400><s200><s210>62</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 62Lys Val Leu Gly Val Asn Val Met Leu1               5</s400><s200><s210>63</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 63Met Met Glu Glu Met Ile Phe Asn Leu1               5</s400><s200><s210>64</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 64Phe Leu Asp Pro Asp Arg His Phe Leu1               5</s400><s200><s210>65</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 65Thr Met Phe Leu Arg Glu Thr Ser Leu1               5</s400><s200><s210>66</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 66Gly Leu Leu Gln Glu Leu Ser Ser Ile1               5</s400><s200><s210>67</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 67Ser Leu Leu Leu Pro Ser Ile Phe Leu1               5</s400><s200><s210>68</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 68Lys Leu Phe Asp Thr Gln Gln Phe Leu1               5</s400><s200><s210>69</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 69Thr Thr Tyr Glu Gly Ser Ile Thr Val1               5</s400><s200><s210>70</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 70Val Leu Gln Gly Leu Leu Arg Ser Leu1               5</s400><s200><s210>71</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 71Tyr Leu Glu Asp Thr Asp Arg Asn Leu1               5</s400><s200><s210>72</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 72Tyr Leu Thr Asp Leu Gln Val Ser Leu1               5</s400><s200><s210>73</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 73Phe Leu Ile Glu Glu Leu Leu Phe Ala1               5</s400><s200><s210>74</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 74Ser Gln Ser Pro Ser Val Ser Gln Leu1               5</s400><s200><s210>75</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 75Lys Val Val Ser Val Leu Tyr Asn Val1               5</s400><s200><s210>76</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 76Lys Tyr Val Ala Glu Leu Ser Leu Leu1               5</s400><s200><s210>77</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 77Arg Tyr Gly Pro Val Phe Thr Val1               5</s400><s200><s210>78</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 78Ser Phe Ala Pro Arg Ser Ala Val Phe1               5</s400><s200><s210>79</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 79Ser Tyr Asn Glu His Trp Asn Tyr Leu1               5</s400><s200><s210>80</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 80Thr Ala Tyr Met Val Ser Val Ala Ala Phe1               5                   10</s400><s200><s210>81</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 81Val Tyr Asn His Thr Thr Arg Pro Leu1               5</s400><s200><s210>82</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 82Ser Tyr Phe Arg Gly Phe Thr Leu Ile1               5</s400><s200><s210>83</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 83Gly Thr Tyr Ala His Thr Val Asn Arg1               5</s400><s200><s210>84</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 84Lys Leu Gln Pro Ala Gln Thr Ala Ala Lys1               5                   10</s400><s200><s210>85</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 85Val Leu Leu Gly Ser Leu Phe Ser Arg Lys1               5                   10</s400><s200><s210>86</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 86Val Val Leu Leu Gly Ser Leu Phe Ser Arg Lys1               5                   10</s400><s200><s210>87</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 87Ala Val Ala Pro Pro Thr Pro Ala Ser Lys1               5                   10</s400><s200><s210>88</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 88Val Val His Ala Val Phe Ala Leu Lys1               5</s400><s200><s210>89</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 89Arg Val Ala Glu Leu Leu Leu Leu His1               5</s400><s200><s210>90</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 90Lys Val Ala Gly Glu Arg Tyr Val Tyr Lys1               5                   10</s400><s200><s210>91</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 91Arg Ser Leu Arg Tyr Tyr Tyr Glu Lys1               5</s400><s200><s210>92</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 92Ser Val Phe Pro Ile Glu Asn Ile Tyr1               5</s400><s200><s210>93</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 93Lys Ile Leu Glu Glu His Thr Asn Lys1               5</s400><s200><s210>94</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 94Ala Thr Phe Glu Arg Val Leu Leu Arg1               5</s400><s200><s210>95</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 95Gln Ser Met Tyr Tyr Pro Leu Gln Leu Lys1               5                   10</s400><s200><s210>96</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 96Thr Ala Phe Gly Gly Phe Leu Lys Tyr1               5</s400><s200><s210>97</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 97Thr Met Leu Asp Val Glu Gly Leu Phe Tyr1               5                   10</s400><s200><s210>98</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 98Leu Leu Gln Pro Pro Pro Leu Leu Ala Arg1               5                   10</s400><s200><s210>99</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 99Lys Val Val Asp Arg Trp Asn Glu Lys1               5</s400><s200><s210>100</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 100Arg Leu Phe Thr Ser Pro Ile Met Thr Lys1               5                   10</s400><s200><s210>101</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 101Arg Val Phe Thr Ser Ser Ile Lys Thr Lys1               5                   10</s400><s200><s210>102</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 102Ser Val Leu Thr Ser Ser Leu Val Lys1               5</s400><s200><s210>103</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 103Thr Ser Arg Ser Val Asp Glu Ala Tyr1               5</s400><s200><s210>104</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 104Val Leu Ala Asp Ser Val Thr Thr Lys1               5</s400><s200><s210>105</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 105Arg Leu Phe Ser Trp Leu Val Asn Arg1               5</s400><s200><s210>106</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 106Ala Ala Phe Val Pro Leu Leu Leu Lys1               5</s400><s200><s210>107</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 107Arg Leu Gln Glu Trp Lys Ala Leu Lys1               5</s400><s200><s210>108</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 108Val Leu Tyr Pro Val Pro Leu Glu Ser Tyr1               5                   10</s400><s200><s210>109</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 109Lys Thr Phe Thr Ile Lys Arg Phe Leu Ala Lys1               5                   10</s400><s200><s210>110</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 110Ser Ala Ala Pro Pro Ser Tyr Phe Arg1               5</s400><s200><s210>111</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 111Thr Leu Pro Gln Phe Arg Glu Leu Gly Tyr1               5                   10</s400><s200><s210>112</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 112Thr Val Thr Gly Ala Glu Gln Ile Gln Tyr1               5                   10</s400><s200><s210>113</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 113Gln Leu Asp Ser Asn Arg Leu Thr Tyr1               5</s400><s200><s210>114</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 114Val Met Glu Gln Ser Ala Gly Ile Met Tyr1               5                   10</s400><s200><s210>115</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 115Phe Val Asp Asn Gln Tyr Trp Arg Tyr1               5</s400><s200><s210>116</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 116Val Leu Leu Asp Glu Gly Ala Met Leu Leu Tyr1               5                   10</s400><s200><s210>117</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 117Ala Pro Arg Leu Leu Leu Leu Ala Val Leu1               5                   10</s400><s200><s210>118</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 118Ser Pro Ala Ser Arg Ser Ile Ser Leu1               5</s400><s200><s210>119</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 119Ala Pro Leu Pro Arg Pro Gly Ala Val Leu1               5                   10</s400><s200><s210>120</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 120Arg Pro Ala Met Asn Tyr Asp Lys Leu1               5</s400><s200><s210>121</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 121Val Pro Asn Gln Ser Ser Glu Ser Leu1               5</s400><s200><s210>122</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 122Tyr Pro Gly Phe Pro Gln Ser Gln Tyr1               5</s400><s200><s210>123</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 123Lys Pro Ser Glu Ser Ile Tyr Ser Ala Leu1               5                   10</s400><s200><s210>124</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 124Leu Pro Ser Asp Ser His Phe Lys Ile Thr Phe1               5                   10</s400><s200><s210>125</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 125Val Pro Val Tyr Ile Leu Leu Asp Glu Met1               5                   10</s400><s200><s210>126</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 126Lys Pro Gly Pro Glu Asp Lys Leu1               5</s400><s200><s210>127</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 127Ala Pro Arg Ala Gly Ser Gln Val Val1               5</s400><s200><s210>128</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 128Tyr Pro Arg Thr Ile Thr Pro Gly Met1               5</s400><s200><s210>129</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 129Ala Pro Arg Pro Ala Ser Ser Leu1               5</s400><s200><s210>130</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 130Phe Pro Arg Leu Val Gly Pro Asp Phe1               5</s400><s200><s210>131</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 131Ala Pro Thr Glu Asp Leu Lys Ala Leu1               5</s400><s200><s210>132</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 132Ile Pro Gly Pro Ala Gln Ser Thr Ile1               5</s400><s200><s210>133</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 133Met Pro Asn Leu Pro Ser Thr Thr Ser Leu1               5                   10</s400><s200><s210>134</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 134Arg Pro Ile Val Pro Gly Pro Leu Leu1               5</s400><s200><s210>135</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 135Arg Val Arg Ser Thr Ile Ser Ser Leu1               5</s400><s200><s210>136</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 136Ser Pro Phe Ser Ala Glu Glu Ala Asn Ser Leu1               5                   10</s400><s200><s210>137</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 137Ser Pro Gly Ala Thr Ser Arg Gly Thr Leu1               5                   10</s400><s200><s210>138</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 138Ser Pro Met Ala Thr Thr Ser Thr Leu1               5</s400><s200><s210>139</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 139Ser Pro Gln Ser Met Ser Asn Thr Leu1               5</s400><s200><s210>140</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 140Ser Pro Arg Thr Glu Ala Ser Ser Ala Val Leu1               5                   10</s400><s200><s210>141</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 141Ser Pro Met Thr Ser Leu Leu Thr Ser Gly Leu1               5                   10</s400><s200><s210>142</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 142Thr Pro Gly Leu Arg Glu Thr Ser Ile1               5</s400><s200><s210>143</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 143Ser Pro Ala Met Thr Ser Thr Ser Phe1               5</s400><s200><s210>144</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 144Ser Pro Ser Pro Val Ser Ser Thr Leu1               5</s400><s200><s210>145</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 145Ser Pro Ser Ser Pro Met Ser Thr Phe1               5</s400><s200><s210>146</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 146Ile Pro Arg Pro Glu Val Gln Ala Leu1               5</s400><s200><s210>147</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 147Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val1               5                   10</s400><s200><s210>148</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 148Lys Pro Tyr Gly Gly Ser Gly Pro Leu1               5</s400><s200><s210>149</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 149Gly Pro Arg Glu Ala Leu Ser Arg Leu1               5</s400><s200><s210>150</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 150Met Ala Ala Val Lys Gln Ala Leu1               5</s400><s200><s210>151</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 151His Leu Leu Leu Lys Val Leu Ala Phe1               5</s400><s200><s210>152</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 152Met Gly Ser Ala Arg Val Ala Glu Leu1               5</s400><s200><s210>153</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 153Asn Ala Met Leu Arg Lys Val Ala Val1               5</s400><s200><s210>154</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 154Met Leu Arg Lys Ile Ala Val Ala Ala1               5</s400><s200><s210>155</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 155Asn Lys Lys Met Met Lys Arg Leu Met1               5</s400><s200><s210>156</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 156His Val Lys Glu Lys Phe Leu Leu1               5</s400><s200><s210>157</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 157Glu Ala Met Lys Arg Leu Ser Tyr Ile1               5</s400><s200><s210>158</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 158Leu Pro Lys Leu Ala Gly Leu Leu1               5</s400><s200><s210>159</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 159Val Leu Lys His Lys Leu Asp Glu Leu1               5</s400><s200><s210>160</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 160Tyr Pro Lys Ala Arg Leu Ala Phe1               5</s400><s200><s210>161</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 161Ala Leu Lys Thr Thr Thr Thr Ala Leu1               5</s400><s200><s210>162</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 162Gln Ala Lys Thr His Ser Thr Leu1               5</s400><s200><s210>163</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 163Gln Gly Leu Leu Arg Pro Val Phe1               5</s400><s200><s210>164</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 164Ser Ile Lys Thr Lys Ser Ala Glu Met1               5</s400><s200><s210>165</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 165Ser Pro Arg Phe Lys Thr Gly Leu1               5</s400><s200><s210>166</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 166Thr Pro Lys Leu Arg Glu Thr Ser Ile1               5</s400><s200><s210>167</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 167Thr Ser His Glu Arg Leu Thr Thr Leu1               5</s400><s200><s210>168</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 168Thr Ser His Glu Arg Leu Thr Thr Tyr1               5</s400><s200><s210>169</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 169Thr Ser Met Pro Arg Ser Ser Ala Met1               5</s400><s200><s210>170</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 170Tyr Leu Leu Glu Lys Ser Arg Val Ile1               5</s400><s200><s210>171</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 171Phe Ala Phe Arg Lys Glu Ala Leu1               5</s400><s200><s210>172</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 172Lys Leu Lys Glu Arg Asn Arg Glu Leu1               5</s400><s200><s210>173</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 173Ala Glu Ala Gln Val Gly Asp Glu Arg Asp Tyr1               5                   10</s400><s200><s210>174</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 174Ala Glu Ala Thr Ala Arg Leu Asn Val Phe1               5                   10</s400><s200><s210>175</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 175Ala Glu Ile Glu Pro Lys Ala Asp Gly1               5</s400><s200><s210>176</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 176Ala Glu Ile Glu Pro Lys Ala Asp Gly Ser Trp1               5                   10</s400><s200><s210>177</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 177Thr Glu Val Gly Thr Met Asn Leu Phe1               5</s400><s200><s210>178</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 178Asn Glu Leu Phe Arg Asp Gly Val Asn Trp1               5                   10</s400><s200><s210>179</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 179Arg Glu Ala Gly Asp Glu Phe Glu Leu1               5</s400><s200><s210>180</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 180Arg Glu Ala Gly Asp Glu Phe Glu Leu Arg Tyr1               5                   10</s400><s200><s210>181</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 181Gly Glu Gly Pro Lys Thr Ser Trp1               5</s400><s200><s210>182</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 182Lys Glu Ala Thr Glu Ala Gln Ser Leu1               5</s400><s200><s210>183</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 183Tyr Glu Lys Gly Ile Met Gln Lys Val1               5</s400><s200><s210>184</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 184Ala Glu Leu Glu Ala Leu Thr Asp Leu Trp1               5                   10</s400><s200><s210>185</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 185Ala Glu Arg Gln Pro Gly Ala Ala Ser Leu1               5                   10</s400><s200><s210>186</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 186Arg Glu Gly Pro Glu Glu Pro Gly Leu1               5</s400><s200><s210>187</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 187Gly Glu Ala Gln Thr Arg Ile Ala Trp1               5</s400><s200><s210>188</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 188Ala Glu Phe Ala Lys Lys Gln Pro Trp Trp1               5                   10</s400><s200><s210>189</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 189Lys Glu Phe Leu Phe Asn Met Tyr1               5</s400><s200><s210>190</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 190Tyr Glu Val Ala Arg Ile Leu Asn Leu1               5</s400><s200><s210>191</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 191Glu Glu Asp Ala Ala Leu Phe Lys Ala Trp1               5                   10</s400><s200><s210>192</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 192Tyr Glu Phe Lys Phe Pro Asn Arg Leu1               5</s400><s200><s210>193</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 193Leu Glu Ala Gln Gln Glu Ala Leu1               5</s400><s200><s210>194</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 194Lys Glu Val Asp Pro Thr Ser His Ser Tyr1               5                   10</s400><s200><s210>195</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 195Ala Glu Asp Lys Arg His Tyr Ser Val1               5</s400><s200><s210>196</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 196Arg Glu Met Pro Gly Gly Pro Val Trp1               5</s400><s200><s210>197</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 197Ala Glu Val Leu Leu Pro Arg Leu Val1               5</s400><s200><s210>198</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 198Gln Glu Ala Ala Arg Ala Ala Leu1               5</s400><s200><s210>199</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 199Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr1               5                   10</s400><s200><s210>200</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 200Ala Glu Ser Ile Pro Thr Val Ser Phe1               5</s400><s200><s210>201</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 201Ala Glu Thr Ile Leu Thr Phe His Ala Phe1               5                   10</s400><s200><s210>202</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 202His Glu Ser Glu Ala Thr Ala Ser Trp1               5</s400><s200><s210>203</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 203Ile Glu His Ser Thr Gln Ala Gln Asp Thr Leu1               5                   10</s400><s200><s210>204</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 204Arg Glu Thr Ser Thr Ser Glu Glu Thr Ser Leu1               5                   10</s400><s200><s210>205</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 205Ser Glu Ile Thr Arg Ile Glu Met1               5</s400><s200><s210>206</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 206Ser Glu Ser Val Thr Ser Arg Thr Ser Tyr1               5                   10</s400><s200><s210>207</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 207Thr Glu Ala Arg Ala Thr Ser Asp Ser Trp1               5                   10</s400><s200><s210>208</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 208Thr Glu Val Ser Arg Thr Glu Ala Ile1               5</s400><s200><s210>209</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 209Thr Glu Val Ser Arg Thr Glu Leu1               5</s400><s200><s210>210</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 210Val Glu Ala Ala Asp Ile Phe Gln Asn Phe1               5                   10</s400><s200><s210>211</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 211Glu Glu Lys Val Phe Pro Ser Pro Leu Trp1               5                   10</s400><s200><s210>212</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 212Met Glu Gln Lys Gln Leu Gln Lys Arg Phe1               5                   10</s400><s200><s210>213</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 213Lys Glu Ser Ile Pro Arg Trp Tyr Tyr1               5</s400><s200><s210>214</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 214Val Glu Gln Thr Arg Ala Gly Ser Leu Leu1               5                   10</s400><s200><s210>215</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 215Ser Glu Asp Gly Leu Pro Glu Gly Ile His Leu1               5                   10</s400><s200><s210>216</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 216Ile Met Phe Asp Asp Ala Ile Glu Arg Ala1               5                   10</s400><s200><s210>217</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 217Val Ser Ser Ser Leu Thr Leu Lys Val1               5</s400><s200><s210>218</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 218Thr Ile Ala Ser Gln Arg Leu Thr Pro Leu1               5                   10</s400><s200><s210>219</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 219Pro Leu Pro Arg Pro Gly Ala Val Leu1               5</s400><s200><s210>220</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 220Arg Met Thr Thr Gln Leu Leu Leu Leu1               5</s400><s200><s210>221</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 221Ser Leu Leu Asp Leu Tyr Gln Leu1               5</s400><s200><s210>222</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 222Ala Leu Met Arg Leu Ile Gly Cys Pro Leu1               5                   10</s400><s200><s210>223</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 223Phe Ala His His Gly Arg Ser Leu1               5</s400><s200><s210>224</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 224Ser Leu Pro Arg Phe Gln Val Thr Leu1               5</s400><s200><s210>225</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 225Ser Val Phe Ala His Pro Arg Lys Leu1               5</s400><s200><s210>226</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 226Gln Val Asp Pro Lys Lys Arg Ile Ser Met1               5                   10</s400><s200><s210>227</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 227Tyr Thr Phe Arg Tyr Pro Leu Ser Leu1               5</s400><s200><s210>228</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 228Arg Leu Trp Asp Trp Val Pro Leu Ala1               5</s400><s200><s210>229</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 229Ile Ser Val Pro Ala Lys Thr Ser Leu1               5</s400><s200><s210>230</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 230Ser Ala Phe Arg Glu Gly Thr Ser Leu1               5</s400><s200><s210>231</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 231Ser Val Thr Glu Ser Thr His His Leu1               5</s400><s200><s210>232</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 232Thr Ile Ser Ser Leu Thr His Glu Leu1               5</s400><s200><s210>233</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 233Gly Ser Asp Thr Ser Ser Lys Ser Leu1               5</s400><s200><s210>234</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 234Gly Val Ala Thr Arg Val Asp Ala Ile1               5</s400><s200><s210>235</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 235Ser Ala Ile Glu Thr Ser Ala Val Leu1               5</s400><s200><s210>236</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 236Ser Ala Ile Pro Phe Ser Met Thr Leu1               5</s400><s200><s210>237</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 237Ser Ala Met Gly Thr Ile Ser Ile Met1               5</s400><s200><s210>238</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 238Pro Leu Leu Val Leu Phe Thr Ile1               5</s400><s200><s210>239</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 239Phe Ala Val Pro Thr Gly Ile Ser Met1               5</s400><s200><s210>240</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 240Phe Ser Thr Asp Thr Ser Ile Val Leu1               5</s400><s200><s210>241</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 241Arg Gln Pro Asn Ile Leu Val His Leu1               5</s400><s200><s210>242</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 242Ser Thr Ile Pro Ala Leu His Glu Ile1               5</s400><s200><s210>243</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 243Tyr Ala Ser Glu Gly Val Lys Gln Val1               5</s400><s200><s210>244</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 244Asp Thr Asp Ser Ser Val His Val Gln Val1               5                   10</s400><s200><s210>245</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 245Leu Ala Val Glu Gly Gly Gln Ser Leu1               5</s400><s200><s210>246</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 246Arg Tyr Leu Ala Val Val His Ala Val Phe1               5                   10</s400><s200><s210>247</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 247Ala Arg Pro Pro Trp Met Trp Val Leu1               5</s400><s200><s210>248</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 248Ser Val Ile Gln His Leu Gly Tyr1               5</s400><s200><s210>249</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 249Val Tyr Thr Pro Thr Leu Gly Thr Leu1               5</s400><s200><s210>250</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 250His Phe Pro Glu Lys Thr Thr His Ser Phe1               5                   10</s400><s200><s210>251</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 251Lys Gln Arg Gln Val Leu Ile Phe Phe1               5</s400><s200><s210>252</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 252Leu Tyr Gln Pro Arg Ala Ser Glu Met1               5</s400><s200><s210>253</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 253Ala Tyr Pro Glu Ile Glu Lys Phe1               5</s400><s200><s210>254</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 254Ile Ile Gln His Leu Thr Glu Gln Phe1               5</s400><s200><s210>255</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 255Val Phe Val Ser Phe Ser Ser Leu Phe1               5</s400><s200><s210>256</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 256Arg Thr Glu Glu Val Leu Leu Thr Phe Lys1               5                   10</s400><s200><s210>257</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 257Val Thr Ala Asp His Ser His Val Phe1               5</s400><s200><s210>258</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 258Gly Ala Tyr Ala His Thr Val Asn Arg1               5</s400><s200><s210>259</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 259Lys Thr Leu Glu Leu Arg Val Ala Tyr1               5</s400><s200><s210>260</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 260Gly Thr Asn Thr Val Ile Leu Glu Tyr1               5</s400><s200><s210>261</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 261His Thr Phe Gly Leu Phe Tyr Gln Arg1               5</s400><s200><s210>262</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 262Arg Ser Arg Leu Asn Pro Leu Val Gln Arg1               5                   10</s400><s200><s210>263</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 263Ser Ser Ser Ser Ala Thr Ile Ser Lys1               5</s400><s200><s210>264</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 264Ala Ile Lys Val Ile Pro Thr Val Phe Lys1               5                   10</s400><s200><s210>265</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 265Gln Ile His Asp His Val Asn Pro Lys1               5</s400><s200><s210>266</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 266Ile Ser Tyr Ser Gly Gln Phe Leu Val Lys1               5                   10</s400><s200><s210>267</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 267Val Thr Asp Leu Ile Ser Pro Arg Lys1               5</s400><s200><s210>268</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 268Gly Leu Leu Gly Leu Ser Leu Arg Tyr1               5</s400><s200><s210>269</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 269Arg Leu Lys Gly Asp Ala Trp Val Tyr Lys1               5                   10</s400><s200><s210>270</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 270Ala Val Phe Asn Pro Arg Phe Tyr Arg Thr Tyr1               5                   10</s400><s200><s210>271</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 271Arg Met Phe Ala Asp Asp Leu His Asn Leu Asn Lys1               5                   10</s400><s200><s210>272</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 272Arg Gln Pro Glu Arg Thr Ile Leu Arg Pro Arg1               5                   10</s400><s200><s210>273</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 273Arg Val Asn Ala Ile Pro Phe Thr Tyr1               5</s400><s200><s210>274</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 274Lys Thr Phe Pro Ala Ser Thr Val Phe1               5</s400><s200><s210>275</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 275Ser Thr Thr Phe Pro Thr Leu Thr Lys1               5</s400><s200><s210>276</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 276Val Ser Lys Thr Thr Gly Met Glu Phe1               5</s400><s200><s210>277</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 277Thr Thr Ala Leu Lys Thr Thr Ser Arg1               5</s400><s200><s210>278</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 278Asn Leu Ser Ser Ile Thr His Glu Arg1               5</s400><s200><s210>279</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 279Ser Val Ser Ser Glu Thr Thr Lys Ile Lys Arg1               5                   10</s400><s200><s210>280</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 280Ser Val Ser Gly Val Lys Thr Thr Phe1               5</s400><s200><s210>281</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 281Arg Ala Lys Glu Leu Glu Ala Thr Phe1               5</s400><s200><s210>282</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 282Cys Leu Thr Arg Thr Gly Leu Phe Leu Arg Phe1               5                   10</s400><s200><s210>283</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 283Ile Val Gln Glu Pro Thr Glu Glu Lys1               5</s400><s200><s210>284</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 284Lys Ser Leu Ile Lys Ser Trp Lys Lys1               5</s400><s200><s210>285</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 285Gly Thr Val Asn Pro Thr Val Gly Lys1               5</s400><s200><s210>286</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 286Thr Val Ala Pro Pro Gln Gly Val Val Lys1               5                   10</s400><s200><s210>287</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 287Arg Arg Ile His Thr Gly Glu Lys Pro Tyr Lys1               5                   10</s400><s200><s210>288</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 288Ser Pro Val Thr Ser Val His Gly Gly Thr Tyr1               5                   10</s400><s200><s210>289</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 289Arg Trp Glu Lys Thr Asp Leu Thr Tyr1               5</s400><s200><s210>290</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 290Asp Met Asp Glu Glu Ile Glu Ala Glu Tyr1               5                   10</s400><s200><s210>291</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 291Glu Thr Ile Arg Ser Val Gly Tyr Tyr1               5</s400><s200><s210>292</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 292Asn Val Thr Met Lys Val Val Ser Val Leu Tyr1               5                   10</s400><s200><s210>293</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 293Val Pro Asp Ser Gly Ala Thr Ala Thr Ala Tyr1               5                   10</s400><s200><s210>294</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 294Tyr Pro Leu Arg Gly Ser Ser Ile Phe1               5</s400><s200><s210>295</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 295Tyr Pro Leu Arg Gly Ser Ser Ile Phe Gly Leu1               5                   10</s400><s200><s210>296</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 296Tyr Pro Leu Arg Gly Ser Ser Ile1               5</s400><s200><s210>297</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 297Thr Val Arg Glu Ala Ser Gly Leu Leu1               5</s400><s200><s210>298</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 298Tyr Pro Thr Glu His Val Gln Phe1               5</s400><s200><s210>299</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 299His Pro Gly Ser Ser Ala Leu His Tyr1               5</s400><s200><s210>300</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 300Ile Pro Met Ala Ala Val Lys Gln Ala Leu1               5                   10</s400><s200><s210>301</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 301Ser Pro Arg Arg Ser Pro Arg Ile Ser Phe1               5                   10</s400><s200><s210>302</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 302Arg Val Glu Glu Val Arg Ala Leu Leu1               5</s400><s200><s210>303</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 303Leu Pro Met Trp Lys Val Thr Ala Phe1               5</s400><s200><s210>304</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 304Leu Pro Arg Pro Gly Ala Val Leu1               5</s400><s200><s210>305</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 305Thr Pro Trp Ala Glu Ser Ser Thr Lys Phe1               5                   10</s400><s200><s210>306</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 306Ala Pro Val Ile Phe Ser His Ser Ala1               5</s400><s200><s210>307</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 307Leu Pro Tyr Gly Pro Gly Ser Glu Ala Ala Ala Phe1               5                   10</s400><s200><s210>308</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 308Tyr Pro Glu Gly Ala Ala Tyr Glu Phe1               5</s400><s200><s210>309</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 309Phe Pro Gln Ser Gln Tyr Pro Gln Tyr1               5</s400><s200><s210>310</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 310Arg Pro Asn Pro Ile Thr Ile Ile Leu1               5</s400><s200><s210>311</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 311Arg Pro Leu Phe Tyr Val Val Ser Leu1               5</s400><s200><s210>312</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 312Leu Pro Tyr Phe Arg Glu Phe Ser Met1               5</s400><s200><s210>313</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 313Lys Val Lys Ser Asp Arg Ser Val Phe1               5</s400><s200><s210>314</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 314Val Pro Asp Gln Pro His Pro Glu Ile1               5</s400><s200><s210>315</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 315Ser Pro Arg Glu Asn Phe Pro Asp Thr Leu1               5                   10</s400><s200><s210>316</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 316Glu Pro Lys Thr Ala Thr Val Leu1               5</s400><s200><s210>317</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 317Phe Pro Phe Gln Pro Gly Ser Val1               5</s400><s200><s210>318</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 318Phe Pro Asn Arg Leu Asn Leu Glu Ala1               5</s400><s200><s210>319</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 319Ser Pro Ala Glu Pro Ser Val Tyr Ala Thr Leu1               5                   10</s400><s200><s210>320</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 320Phe Pro Met Ser Pro Val Thr Ser Val1               5</s400><s200><s210>321</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 321Ser Pro Met Asp Thr Phe Leu Leu Ile1               5</s400><s200><s210>322</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 322Ser Pro Asp Pro Ser Lys His Leu Leu1               5</s400><s200><s210>323</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 323Arg Pro Met Pro Asn Leu Arg Ser Val1               5</s400><s200><s210>324</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 324Val Pro Tyr Arg Val Val Gly Leu1               5</s400><s200><s210>325</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 325Gly Pro Arg Asn Ala Gln Arg Val Leu1               5</s400><s200><s210>326</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 326Val Pro Ser Glu Ile Asp Ala Ala Phe1               5</s400><s200><s210>327</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 327Ser Pro Leu Pro Val Thr Ser Leu Ile1               5</s400><s200><s210>328</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 328Glu Pro Val Thr Ser Ser Leu Pro Asn Phe1               5                   10</s400><s200><s210>329</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 329Phe Pro Ala Met Thr Glu Ser Gly Gly Met Ile Leu1               5                   10</s400><s200><s210>330</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 330Phe Pro Phe Val Thr Gly Ser Thr Glu Met1               5                   10</s400><s200><s210>331</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 331Phe Pro His Pro Glu Met Thr Thr Ser Met1               5                   10</s400><s200><s210>332</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 332Phe Pro His Ser Glu Met Thr Thr Leu1               5</s400><s200><s210>333</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 333Phe Pro His Ser Glu Met Thr Thr Val Met1               5                   10</s400><s200><s210>334</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 334Phe Pro Tyr Ser Glu Val Thr Thr Leu1               5</s400><s200><s210>335</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 335His Pro Asp Pro Val Gly Pro Gly Leu1               5</s400><s200><s210>336</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 336His Pro Lys Thr Glu Ser Ala Thr Pro Ala Ala Tyr1               5                   10</s400><s200><s210>337</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 337His Pro Val Glu Thr Ser Ser Ala Leu1               5</s400><s200><s210>338</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 338His Val Thr Lys Thr Gln Ala Thr Phe1               5</s400><s200><s210>339</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 339Leu Pro Ala Gly Thr Thr Gly Ser Leu Val Phe1               5                   10</s400><s200><s210>340</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 340Leu Pro Glu Ile Ser Thr Arg Thr Met1               5</s400><s200><s210>341</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 341Leu Pro Leu Asp Thr Ser Thr Thr Leu1               5</s400><s200><s210>342</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 342Leu Pro Leu Gly Thr Ser Met Thr Phe1               5</s400><s200><s210>343</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 343Leu Pro Ser Val Ser Gly Val Lys Thr Thr Phe1               5                   10</s400><s200><s210>344</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 344Leu Pro Thr Gln Thr Thr Ser Ser Leu1               5</s400><s200><s210>345</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 345Leu Pro Thr Ser Glu Ser Leu Val Ser Phe1               5                   10</s400><s200><s210>346</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 346Leu Pro Trp Asp Thr Ser Thr Thr Leu Phe1               5                   10</s400><s200><s210>347</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 347Met Pro Leu Thr Thr Gly Ser Gln Gly Met1               5                   10</s400><s200><s210>348</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 348Met Pro Asn Ser Ala Ile Pro Phe Ser Met1               5                   10</s400><s200><s210>349</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 349Met Pro Ser Leu Ser Glu Ala Met Thr Ser Phe1               5                   10</s400><s200><s210>350</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 350Asn Pro Ser Ser Thr Thr Thr Glu Phe1               5</s400><s200><s210>351</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 351Asn Val Leu Thr Ser Thr Pro Ala Phe1               5</s400><s200><s210>352</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 352Ser Pro Ala Glu Thr Ser Thr Asn Met1               5</s400><s200><s210>353</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 353Ser Pro Ala Met Thr Thr Pro Ser Leu1               5</s400><s200><s210>354</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 354Ser Pro Leu Pro Val Thr Ser Leu Leu1               5</s400><s200><s210>355</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 355Ser Pro Leu Val Thr Ser His Ile Met1               5</s400><s200><s210>356</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 356Ser Pro Asn Glu Phe Tyr Phe Thr Val1               5</s400><s200><s210>357</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 357Ser Pro Ser Pro Val Pro Thr Thr Leu1               5</s400><s200><s210>358</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 358Ser Pro Ser Pro Val Thr Ser Thr Leu1               5</s400><s200><s210>359</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 359Ser Pro Ser Thr Ile Lys Leu Thr Met1               5</s400><s200><s210>360</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 360Ser Pro Ser Val Ser Ser Asn Thr Tyr1               5</s400><s200><s210>361</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 361Ser Pro Thr His Val Thr Gln Ser Leu1               5</s400><s200><s210>362</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 362Ser Pro Val Pro Val Thr Ser Leu Phe1               5</s400><s200><s210>363</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 363Thr Ala Lys Thr Pro Asp Ala Thr Phe1               5</s400><s200><s210>364</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 364Thr Pro Leu Ala Thr Thr Gln Arg Phe1               5</s400><s200><s210>365</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 365Thr Pro Leu Ala Thr Thr Gln Arg Phe Thr Tyr1               5                   10</s400><s200><s210>366</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 366Thr Pro Leu Thr Thr Thr Gly Ser Ala Glu Met1               5                   10</s400><s200><s210>367</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 367Thr Pro Ser Val Val Thr Glu Gly Phe1               5</s400><s200><s210>368</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 368Val Pro Thr Pro Val Phe Pro Thr Met1               5</s400><s200><s210>369</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 369Phe Pro His Ser Glu Met Thr Thr Val1               5</s400><s200><s210>370</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 370Pro Gly Gly Thr Arg Gln Ser Leu1               5</s400><s200><s210>371</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 371Leu Tyr Val Asp Gly Phe Thr His Trp1               5</s400><s200><s210>372</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 372Ile Pro Arg Asn Pro Pro Pro Thr Leu Leu1               5                   10</s400><s200><s210>373</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 373Arg Pro Arg Ala Leu Arg Asp Leu Arg Ile Leu1               5                   10</s400><s200><s210>374</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 374Asn Pro Ile Gly Asp Thr Gly Val Lys Phe1               5                   10</s400><s200><s210>375</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 375Ala Ala Ala Ser Pro Leu Leu Leu Leu1               5</s400><s200><s210>376</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 376Arg Pro Arg Ser Pro Ala Gly Gln Val Ala1               5                   10</s400><s200><s210>377</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 377Arg Pro Arg Ser Pro Ala Gly Gln Val Ala Ala Ala1               5                   10</s400><s200><s210>378</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 378Arg Pro Arg Ser Pro Ala Gly Gln Val Ala Ala1               5                   10</s400><s200><s210>379</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 379Gly Pro Phe Pro Leu Val Tyr Val Leu1               5</s400><s200><s210>380</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 380Ile Pro Thr Tyr Gly Arg Thr Phe1               5</s400><s200><s210>381</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 381Leu Pro Glu Gln Thr Pro Leu Ala Phe1               5</s400><s200><s210>382</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 382Ser Pro Met His Asp Arg Trp Thr Phe1               5</s400><s200><s210>383</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 383Thr Pro Thr Lys Glu Thr Val Ser Leu1               5</s400><s200><s210>384</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 384Tyr Pro Gly Leu Arg Gly Ser Pro Met1               5</s400><s200><s210>385</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 385Ser Pro Ala Leu His Ile Gly Ser Val1               5</s400><s200><s210>386</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 386Phe Pro Phe Asn Pro Leu Asp Phe1               5</s400><s200><s210>387</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 387Ala Pro Leu Lys Leu Ser Arg Thr Pro Ala1               5                   10</s400><s200><s210>388</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 388Ser Pro Ala Pro Leu Lys Leu Ser Arg Thr Pro Ala1               5                   10</s400><s200><s210>389</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 389Ser Pro Gly Ala Gln Arg Thr Phe Phe Gln Leu1               5                   10</s400><s200><s210>390</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 390Asn Pro Asp Leu Arg Arg Asn Val Leu1               5</s400><s200><s210>391</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 391Ala Pro Ser Thr Pro Arg Ile Thr Thr Phe1               5                   10</s400><s200><s210>392</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 392Lys Pro Ile Glu Ser Thr Leu Val Ala1               5</s400><s200><s210>393</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 393Ala Ser Lys Pro His Val Glu Ile1               5</s400><s200><s210>394</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 394Met Tyr Lys Met Lys Lys Pro Ile1               5</s400><s200><s210>395</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 395Val Leu Leu Pro Arg Leu Val Ser Cys1               5</s400><s200><s210>396</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 396Arg Glu Ala Ser Gly Leu Leu Ser Leu1               5</s400><s200><s210>397</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 397Arg Glu Gly Asp Thr Val Gln Leu Leu1               5</s400><s200><s210>398</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 398Ser Phe Glu Gln Val Val Asn Glu Leu Phe1               5                   10</s400><s200><s210>399</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 399Arg Glu Leu Leu His Leu Val Thr Leu1               5</s400><s200><s210>400</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 400Gly Glu Ile Glu Ile His Leu Leu1               5</s400><s200><s210>401</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 401Glu Asp Leu Lys Glu Glu Leu Leu Leu1               5</s400><s200><s210>402</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 402Arg Glu Leu Ala Asn Asp Glu Leu Ile Leu1               5                   10</s400><s200><s210>403</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 403Glu Glu Ala Gln Trp Val Arg Lys Tyr1               5</s400><s200><s210>404</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 404Asn Glu Ala Ile Met His Gln Tyr1               5</s400><s200><s210>405</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 405Asn Glu Ile Trp Thr His Ser Tyr1               5</s400><s200><s210>406</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 406Glu Asp Gly Arg Leu Val Ile Glu Phe1               5</s400><s200><s210>407</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 407Ala Glu His Glu Gly Val Ser Val Leu1               5</s400><s200><s210>408</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 408Leu Glu Lys Ala Leu Gln Val Phe1               5</s400><s200><s210>409</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 409Arg Glu Phe Val Leu Ser Lys Gly Asp Ala Gly Leu1               5                   10</s400><s200><s210>410</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 410Ser Glu Asp Pro Ser Lys Leu Glu Ala1               5</s400><s200><s210>411</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 411Leu Glu Leu Pro Pro Ile Leu Val Tyr1               5</s400><s200><s210>412</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 412Gln Glu Ile Leu Thr Gln Val Lys Gln1               5</s400><s200><s210>413</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 413Ile Glu Ala Leu Ser Gly Lys Ile Glu Leu1               5                   10</s400><s200><s210>414</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 414Glu Asp Ala Ala Leu Phe Lys Ala Trp1               5</s400><s200><s210>415</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 415Arg Glu Glu Asp Ala Ala Leu Phe Lys Ala Trp1               5                   10</s400><s200><s210>416</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 416Ser Glu Glu Glu Thr Arg Val Val Phe1               5</s400><s200><s210>417</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 417Ala Glu His Phe Ser Met Ile Arg Ala1               5</s400><s200><s210>418</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 418Phe Glu Asp Ala Gln Gly His Ile Trp1               5</s400><s200><s210>419</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 419His Glu Phe Gly His Val Leu Gly Leu1               5</s400><s200><s210>420</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 420Phe Glu Ser His Ser Thr Val Ser Ala1               5</s400><s200><s210>421</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 421Gly Glu Pro Ala Thr Thr Val Ser Leu1               5</s400><s200><s210>422</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 422Ser Glu Thr Thr Phe Ser Leu Ile Phe1               5</s400><s200><s210>423</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 423Ser Glu Val Pro Thr Gly Thr Thr Ala1               5</s400><s200><s210>424</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 424Thr Glu Phe Pro Leu Phe Ser Ala Ala1               5</s400><s200><s210>425</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 425Ser Glu Val Pro Leu Pro Met Ala Ile1               5</s400><s200><s210>426</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 426Pro Glu Lys Thr Thr His Ser Phe1               5</s400><s200><s210>427</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 427His Glu Ser Ser Ser His His Asp Leu1               5</s400><s200><s210>428</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 428Leu Asp Leu Gly Leu Asn His Ile1               5</s400><s200><s210>429</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 429Arg Glu Lys Phe Ile Ala Ser Val Ile1               5</s400><s200><s210>430</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 430Asp Glu Lys Ile Leu Tyr Pro Glu Phe1               5</s400><s200><s210>431</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 431Ala Glu Gln Asp Pro Asp Glu Leu Asn Lys Ala1               5                   10</s400><s200><s210>432</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 432Glu Glu Gln Tyr Ile Ala Gln Phe1               5</s400><s200><s210>433</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 433Ser Asp Ser Gln Val Arg Ala Phe1               5</s400><s200><s210>434</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 434Lys Glu Ala Ile Arg Glu His Gln Met1               5</s400><s200><s210>435</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 435Arg Glu Glu Phe Val Ser Ile Asp His Leu1               5                   10</s400><s200><s210>436</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 436Arg Glu Pro Gly Asp Ile Phe Ser Glu Leu1               5                   10</s400><s200><s210>437</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 437Thr Glu Ala Val Val Thr Asn Glu Leu1               5</s400><s200><s210>438</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 438Ser Glu Val Asp Ser Pro Asn Val Leu1               5</s400><s200><s210>439</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 439Glu Ala Leu Ala Lys Leu Met Ser Leu1               5</s400><s200><s210>440</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 440Glu Leu Phe Glu Gly Leu Lys Ala Phe1               5</s400><s200><s210>441</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 441His Gln Ile Thr Glu Val Gly Thr Met1               5</s400><s200><s210>442</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 442Ile Leu Ser Lys Leu Thr Asp Ile Gln Tyr1               5                   10</s400><s200><s210>443</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 443Gly Thr Phe Asn Pro Val Ser Leu Trp1               5</s400><s200><s210>444</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 444Lys Leu Ser Gln Lys Gly Tyr Ser Trp1               5</s400><s200><s210>445</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 445Leu His Ile Thr Pro Gly Thr Ala Tyr1               5</s400><s200><s210>446</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 446Gly Arg Ile Val Ala Phe Phe Ser Phe1               5</s400><s200><s210>447</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 447Met Gln Val Leu Val Ser Arg Ile1               5</s400><s200><s210>448</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 448Leu Ser Gln Lys Gly Tyr Ser Trp1               5</s400><s200><s210>449</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 449Arg Ala Phe Ser Asp Leu Thr Ser Gln Leu1               5                   10</s400><s200><s210>450</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 450Lys Gln Thr Phe Pro Phe Pro Thr Ile1               5</s400><s200><s210>451</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 451Asp Tyr Leu Asn Glu Trp Gly Ser Arg Phe1               5                   10</s400><s200><s210>452</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 452Leu Lys Val Leu Gly Val Asn Val Met1               5</s400><s200><s210>453</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 453Asp Val Lys Leu Glu Lys Pro Lys1               5</s400><s200><s210>454</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 454Ala Gln Thr Asp Pro Thr Thr Gly Tyr1               5</s400><s200><s210>455</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 455Ala Ala Ala Ala Asn Ala Gln Val Tyr1               5</s400><s200><s210>456</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 456Ile Pro Leu Glu Arg Pro Leu Gly Glu Val Tyr1               5                   10</s400><s200><s210>457</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 457Asn Ala Ala Ala Ala Ala Asn Ala Gln Val Tyr1               5                   10</s400><s200><s210>458</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 458Thr Asp Thr Leu Ile His Leu Met1               5</s400><s200><s210>459</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 459Lys Val Ala Gly Glu Arg Tyr Val Tyr1               5</s400><s200><s210>460</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 460Arg Leu Ser Ser Ala Thr Ala Asn Ala Leu Tyr1               5                   10</s400><s200><s210>461</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 461Ala Gln Arg Met Thr Thr Gln Leu Leu1               5</s400><s200><s210>462</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 462Gln Arg Met Thr Thr Gln Leu Leu Leu1               5</s400><s200><s210>463</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 463Val Asn Gln Ser Leu Leu Asp Leu Tyr1               5</s400><s200><s210>464</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 464Met Ser Ala Leu Arg Pro Leu Leu1               5</s400><s200><s210>465</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 465Asp Leu Ile Glu Ser Gly Gln Leu Arg1               5</s400><s200><s210>466</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 466Asp Leu Ile Glu Ser Gly Gln Leu Arg Glu Arg1               5                   10</s400><s200><s210>467</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 467Met Gln Met Gln Glu Arg Asp Thr Leu1               5</s400><s200><s210>468</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 468Ala Leu Ala Lys Leu Leu Pro Leu1               5</s400><s200><s210>469</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 469Gln Glu Gln Ser Ser Val Val Arg Ala1               5</s400><s200><s210>470</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 470Gln Gly Glu Arg Leu Leu Gly Ala Ala Val1               5                   10</s400><s200><s210>471</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 471Ala Gln Arg Leu Asp Pro Val Tyr Phe1               5</s400><s200><s210>472</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 472Met Arg Leu Leu Val Ala Pro Leu1               5</s400><s200><s210>473</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 473Met Leu Asn Asn Asn Ala Leu Ser Ala Leu1               5                   10</s400><s200><s210>474</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 474Ala Ala Asp Gly Gly Leu Arg Ala Ser Val Thr Leu1               5                   10</s400><s200><s210>475</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 475Gly Arg Asp Pro Thr Ser Tyr Pro Ser Leu1               5                   10</s400><s200><s210>476</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 476Ile Ser Tyr Pro Pro Leu His Glu Trp1               5</s400><s200><s210>477</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 477Arg Ile Gln Gln Gln Thr Asn Thr Tyr1               5</s400><s200><s210>478</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 478Val Val Gly Pro Lys Gly Ala Thr Ile1               5</s400><s200><s210>479</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 479Thr Glu Gly Ser His Phe Val Glu Ala1               5</s400><s200><s210>480</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 480Gly Arg Ala Asp Ile Met Ile Asp Phe1               5</s400><s200><s210>481</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 481Gly Arg Trp Glu Lys Thr Asp Leu Thr Tyr1               5                   10</s400><s200><s210>482</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 482Gly Arg Trp Glu Lys Thr Asp Leu Thr Tyr Arg1               5                   10</s400><s200><s210>483</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 483Val Arg Phe Pro Val His Ala Ala Leu Val Trp1               5                   10</s400><s200><s210>484</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 484Ala Trp Leu Arg Ser Ala Ala Ala1               5</s400><s200><s210>485</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 485Val Arg Phe Pro Val His Ala Ala Leu1               5</s400><s200><s210>486</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 486Asp Arg Phe Phe Trp Leu Lys Val1               5</s400><s200><s210>487</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 487Gly Met Ala Asp Ile Leu Val Val Phe1               5</s400><s200><s210>488</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 488Arg Ser Phe Ser Leu Gly Val Pro Arg1               5</s400><s200><s210>489</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 489Glu Val Ser Gly Leu Ser Thr Glu Arg1               5</s400><s200><s210>490</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 490Ala Glu Val Gln Lys Leu Leu Gly Pro1               5</s400><s200><s210>491</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 491Glu Ala Tyr Ser Ser Thr Ser Ser Trp1               5</s400><s200><s210>492</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 492Glu Val Thr Pro Trp Ile Ser Leu Thr Leu1               5                   10</s400><s200><s210>493</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 493Asp Thr Asn Leu Glu Pro Val Thr Arg1               5</s400><s200><s210>494</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 494Glu Thr Thr Ala Ser Leu Val Ser Arg1               5</s400><s200><s210>495</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 495Glu Val Pro Ser Gly Ala Thr Thr Glu Val Ser Arg1               5                   10</s400><s200><s210>496</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 496Glu Val Pro Thr Gly Thr Thr Ala Glu Val Ser Arg1               5                   10</s400><s200><s210>497</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 497Glu Val Ser Arg Thr Glu Val Ile Ser Ser Arg1               5                   10</s400><s200><s210>498</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 498Glu Val Tyr Pro Glu Leu Gly Thr Gln Gly Arg1               5                   10</s400><s200><s210>499</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 499Ser Ser Glu Thr Thr Lys Ile Lys Arg1               5</s400><s200><s210>500</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 500Ala His Val Leu His Ser Thr Leu1               5</s400><s200><s210>501</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 501Ile Gln Ile Glu Pro Thr Ser Ser Leu1               5</s400><s200><s210>502</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 502Ser Gly Asp Gln Gly Ile Thr Ser Leu1               5</s400><s200><s210>503</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 503Thr Val Phe Asp Lys Ala Phe Thr Ala Ala1               5                   10</s400><s200><s210>504</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 504Thr Val Ser Ser Val Asn Gln Gly Leu1               5</s400><s200><s210>505</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 505Tyr Val Pro Thr Gly Ala Ile Thr Gln Ala1               5                   10</s400><s200><s210>506</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 506His Gln Phe Ile Thr Ser Thr Asn Thr Phe1               5                   10</s400><s200><s210>507</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 507Thr Ser Ile Phe Ser Gly Gln Ser Leu1               5</s400><s200><s210>508</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 508Thr Val Ala Lys Thr Thr Thr Thr Phe1               5</s400><s200><s210>509</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 509Gly Arg Gly Pro Gly Gly Val Ser Trp1               5</s400><s200><s210>510</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 510Arg Arg Ile Pro Thr Glu Pro Thr Phe1               5</s400><s200><s210>511</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 511Ser Arg Ile Pro Gln Asp Val Ser Trp1               5</s400><s200><s210>512</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 512Ser Arg Ser Pro Glu Asn Pro Ser Trp1               5</s400><s200><s210>513</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 513Ser Arg Thr Glu Ile Ser Ser Ser Arg1               5</s400><s200><s210>514</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 514Ser Arg Thr Glu Val Ala Ser Ser Arg1               5</s400><s200><s210>515</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 515Thr Arg Ile Glu Met Glu Ser Thr Phe1               5</s400><s200><s210>516</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 516Thr Ala Ser Thr Pro Ile Ser Thr Phe1               5</s400><s200><s210>517</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 517Thr Ala Glu Thr Ile Leu Thr Phe His Ala Phe1               5                   10</s400><s200><s210>518</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 518Thr Ser Asp Phe Pro Thr Ile Thr Val1               5</s400><s200><s210>519</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 519Val Thr Ser Leu Leu Thr Pro Gly Met Val1               5                   10</s400><s200><s210>520</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 520Thr His Ser Ala Met Thr His Gly Phe1               5</s400><s200><s210>521</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 521Thr His Ser Thr Ala Ser Gln Gly Phe1               5</s400><s200><s210>522</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 522Thr His Ser Thr Ile Ser Gln Gly Phe1               5</s400><s200><s210>523</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 523Ala Pro Lys Gly Ile Pro Val Lys Pro Thr Ser Ala1               5                   10</s400><s200><s210>524</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 524Ala Val Ser Pro Thr Val Gln Gly Leu1               5</s400><s200><s210>525</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 525Gln Arg Phe Pro His Ser Glu Met1               5</s400><s200><s210>526</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 526Ser Val Pro Asp Ile Leu Ser Thr1               5</s400><s200><s210>527</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 527Gln Ser Thr Pro Tyr Val Asn Ser Val1               5</s400><s200><s210>528</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 528Thr Arg Thr Gly Leu Phe Leu Arg Phe1               5</s400><s200><s210>529</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 529Pro Phe Ser Asn Pro Arg Val Leu1               5</s400><s200><s210>530</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 530Met Leu Pro Arg Ala Ala Leu Leu1               5</s400><s200><s210>531</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 531Gln Gly Ala Gln Leu Arg Gly Ala Leu1               5</s400><s200><s210>532</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 532Ala Ile Ser Phe Ser Tyr Lys Ala Trp1               5</s400><s200><s210>533</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 533Gly Gln His Leu His Leu Glu Thr Phe1               5</s400><s200><s210>534</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 534Cys Arg Pro Gly Ala Leu Gln Ile Glu Leu1               5                   10</s400><s200><s210>535</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 535Ile Lys Asp Val Arg Lys Ile Lys1               5</s400><s200><s210>536</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 536Val Gln Asp Gln Ala Cys Val Ala Lys Phe1               5                   10</s400><s200><s210>537</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 537Ile Arg Arg Leu Lys Glu Leu Lys Asp Gln1               5                   10</s400><s200><s210>538</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 538Gln Leu Glu Lys Ala Leu Lys Glu Ile1               5</s400><s200><s210>539</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 539Ile Pro Ile Pro Ser Thr Gly Ser Val Glu Met1               5                   10</s400><s200><s210>540</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 540Ala Gly Ile Pro Ala Val Ala Leu Trp1               5</s400><s200><s210>541</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 541Arg Leu Ser Pro Ala Pro Leu Lys Leu1               5</s400><s200><s210>542</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 542Gln Ile Ile Asp Glu Glu Glu Thr Gln Phe1               5                   10</s400><s200><s210>543</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 543Met Arg Leu Ser Pro Ala Pro Leu Lys1               5</s400><s200><s210>544</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 544Leu Arg Asn Pro Ser Ile Gln Lys Leu1               5</s400><s200><s210>545</s210><s211>8</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 545Arg Val Gly Pro Pro Leu Leu Ile1               5</s400><s200><s210>546</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 546Gly Arg Ala Phe Phe Ala Ala Ala Phe1               5</s400><s200><s210>547</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 547Glu Val Asn Lys Pro Gly Val Tyr Thr Arg1               5                   10</s400><s200><s210>548</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 548Val Ser Glu Ala Ser Leu Val Ser Ser Ile1               5                   10</s400><s200><s210>549</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 549Ala Arg Ser Lys Leu Gln Gln Gly Leu1               5</s400><s200><s210>550</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 550Arg Arg Phe Lys Glu Pro Trp Phe Leu1               5</s400><s200><s210>551</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 551Arg Leu His Thr Gly Glu Lys Pro Tyr Lys1               5                   10</s400><s200><s210>552</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 552Gly Val Asn Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys1               5                   10                  15Pro His Val Glu            20</s400><s200><s210>553</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 553Val Asn Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro1               5                   10                  15His Val Glu</s400><s200><s210>554</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 554Gly Val Asn Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys1               5                   10                  15Pro His</s400><s200><s210>555</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 555Val Asn Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro1               5                   10                  15His</s400><s200><s210>556</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 556Asn Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro His1               5                   10                  15</s400><s200><s210>557</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 557Ala Met Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro His1               5                   10                  15</s400><s200><s210>558</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 558Leu Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro His1               5                   10</s400><s200><s210>559</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 559Arg Lys Val Ala Val Ala Ala Ala Ser Lys Pro His1               5                   10</s400><s200><s210>560</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 560Pro Asn Phe Ser Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu1               5                   10                  15Glu Leu Leu Lys            20</s400><s200><s210>561</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 561Pro Asn Phe Ser Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu1               5                   10                  15Glu Leu Leu</s400><s200><s210>562</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 562Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu Lys1               5                   10                  15Val Leu</s400><s200><s210>563</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 563Pro Asn Phe Ser Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu1               5                   10                  15Glu Leu</s400><s200><s210>564</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 564Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu Lys1               5                   10                  15Val</s400><s200><s210>565</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 565Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu Lys Val1               5                   10                  15</s400><s200><s210>566</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 566Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu Lys1               5                   10                  15</s400><s200><s210>567</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 567Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu1               5                   10</s400><s200><s210>568</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 568Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu Lys1               5                   10</s400><s200><s210>569</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 569Trp Lys Ile Ile Arg Ser Glu Asn Phe Glu Glu Leu Leu1               5                   10</s400><s200><s210>570</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 570Gly Asn Trp Lys Ile Ile Arg Ser Glu Asn Phe1               5                   10</s400><s200><s210>571</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 571Pro Asn Phe Ser Gly Asn Trp Lys Ile Ile Arg1               5                   10</s400><s200><s210>572</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 572Ile Asn Phe Lys Val Gly Glu Glu Phe Glu Glu Gln Thr Val1               5                   10</s400><s200><s210>573</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 573Arg Leu Leu Ser Ala Asp Thr Lys Gly Trp Val Arg Leu Gln1               5                   10</s400><s200><s210>574</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 574Leu Pro Asp Phe Tyr Asn Asp Trp Met Phe Ile Ala Lys His Leu Pro1               5                   10                  15Asp Leu</s400><s200><s210>575</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 575Val Gly Asp Asp His Leu Leu Leu Leu Gln Gly Glu Gln Leu Arg Arg1               5                   10                  15Thr</s400><s200><s210>576</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 576Val Gly Asp Asp His Leu Leu Leu Leu Gln Gly Glu Gln Leu Arg Arg1               5                   10                  15</s400><s200><s210>577</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 577Gly Asp Asp His Leu Leu Leu Leu Gln Gly Glu Gln Leu Arg Arg1               5                   10                  15</s400><s200><s210>578</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 578Asp Asp His Leu Leu Leu Leu Gln Gly Glu Gln Leu Arg Arg1               5                   10</s400><s200><s210>579</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 579Ser Gly Gly Pro Leu Val Cys Asp Glu Thr Leu Gln Gly Ile Leu Ser1               5                   10                  15</s400><s200><s210>580</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 580Gly Gly Pro Leu Val Cys Asp Glu Thr Leu Gln Gly Ile Leu Ser1               5                   10                  15</s400><s200><s210>581</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 581Gly Gly Pro Leu Val Cys Asp Glu Thr Leu Gln Gly Ile Leu1               5                   10</s400><s200><s210>582</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 582Gly Ser Gln Pro Trp Gln Val Ser Leu Phe Asn Gly Leu Ser Phe His1               5                   10                  15</s400><s200><s210>583</s210><s211>24</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 583Leu Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys Phe Pro Asn Arg1               5                   10                  15Leu Asn Leu Glu Ala Ile Asn Tyr            20</s400><s200><s210>584</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 584Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys Phe Pro Asn Arg Leu1               5                   10                  15Asn Leu Glu Ala Ile Asn Tyr            20</s400><s200><s210>585</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 585Leu Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys Phe Pro Asn Arg1               5                   10                  15Leu Asn Leu</s400><s200><s210>586</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 586Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys Phe Pro Asn Arg Leu1               5                   10                  15Asn Leu</s400><s200><s210>587</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 587Asp Gln Ala Asn Leu Thr Val Lys Leu Pro Asp Gly Tyr Glu Phe Lys1               5                   10                  15Phe Pro Asn Arg Leu Asn Leu            20</s400><s200><s210>588</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 588Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn Leu Gly Lys Asp Ser1               5                   10                  15Asn Asn Leu</s400><s200><s210>589</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 589Ala Pro Asp Ala Lys Ser Phe Val Leu Asn Leu Gly Lys Asp Ser Asn1               5                   10                  15Asn Leu</s400><s200><s210>590</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 590Arg Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn1               5                   10                  15Leu Gly</s400><s200><s210>591</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 591Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn Leu1               5                   10                  15</s400><s200><s210>592</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 592Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn Leu1               5                   10                  15Gly</s400><s200><s210>593</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 593Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn Leu Gly1               5                   10                  15</s400><s200><s210>594</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 594Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu Asn1               5                   10                  15</s400><s200><s210>595</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 595Val Arg Gly Glu Val Ala Pro Asp Ala Lys Ser Phe Val Leu1               5                   10</s400><s200><s210>596</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 596Met Ala Ala Asp Gly Asp Phe Lys Ile Lys Cys Val Ala Phe Asp1               5                   10                  15</s400><s200><s210>597</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 597Ser Pro Asp Ala Glu Ser Leu Phe Arg Glu Ala Leu Ser Asn Lys Val1               5                   10                  15Asp Glu Leu</s400><s200><s210>598</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 598Ala Glu Ser Leu Phe Arg Glu Ala Leu Ser Asn Lys Val Asp Glu Leu1               5                   10                  15</s400><s200><s210>599</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 599Ala Glu Ser Leu Phe Arg Glu Ala Leu Ser Asn Lys Val Asp Glu1               5                   10                  15</s400><s200><s210>600</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 600Phe Arg Glu Ala Leu Ser Asn Lys Val Asp Glu1               5                   10</s400><s200><s210>601</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 601Leu Ser Asn Lys Val Asp Glu Leu Ala His Phe Leu Leu Arg Lys1               5                   10                  15</s400><s200><s210>602</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 602Lys Asp Pro Val Ala Trp Glu Ala Gly Met Leu Met His1               5                   10</s400><s200><s210>603</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 603Lys Ala Arg Asp Glu Thr Arg Gly Leu Asn Val Pro Gln1               5                   10</s400><s200><s210>604</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 604Lys Leu Ile Thr Gln Asp Leu Val Lys Leu Lys Tyr Leu Glu Tyr Arg1               5                   10                  15Gln</s400><s200><s210>605</s210><s211>25</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 605Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys Ala Glu Glu Arg His Arg Pro            20                  25</s400><s200><s210>606</s210><s211>22</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 606Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys Ala Glu Glu Arg            20</s400><s200><s210>607</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 607Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys Ala Glu Glu            20</s400><s200><s210>608</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 608Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys Ala Glu            20</s400><s200><s210>609</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 609Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys Ala</s400><s200><s210>610</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 610Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu Lys</s400><s200><s210>611</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 611Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15Leu</s400><s200><s210>612</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 612Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly Leu1               5                   10                  15Lys</s400><s200><s210>613</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 613Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15</s400><s200><s210>614</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 614Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly Leu1               5                   10                  15</s400><s200><s210>615</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 615Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly Leu Lys1               5                   10                  15</s400><s200><s210>616</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 616Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10                  15</s400><s200><s210>617</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 617Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly Leu1               5                   10                  15</s400><s200><s210>618</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 618Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10</s400><s200><s210>619</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 619Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu1               5                   10</s400><s200><s210>620</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 620Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly1               5                   10</s400><s200><s210>621</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 621Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly1               5                   10</s400><s200><s210>622</s210><s211>25</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 622Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile1               5                   10                  15Arg Ser Ile Pro Gln Gly Ile Val Ala            20                  25</s400><s200><s210>623</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 623Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser1               5                   10                  15Ile Pro Gln Gly Ile Val Ala            20</s400><s200><s210>624</s210><s211>22</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 624Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile1               5                   10                  15Pro Gln Gly Ile Val Ala            20</s400><s200><s210>625</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 625Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15Ser Ile Pro Gln Gly            20</s400><s200><s210>626</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 626Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro1               5                   10                  15Gln Gly Ile Val Ala            20</s400><s200><s210>627</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 627Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser1               5                   10                  15Ile Pro Gln Gly            20</s400><s200><s210>628</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 628Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15Ser Ile Pro Gln            20</s400><s200><s210>629</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 629Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln1               5                   10                  15Gly Ile Val Ala            20</s400><s200><s210>630</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 630Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser1               5                   10                  15Ile Pro Gln</s400><s200><s210>631</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 631Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15Ser Ile Pro</s400><s200><s210>632</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 632Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly1               5                   10                  15Ile Val Ala</s400><s200><s210>633</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 633Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile1               5                   10                  15Pro Gln</s400><s200><s210>634</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 634Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15Ser</s400><s200><s210>635</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 635Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser1               5                   10                  15</s400><s200><s210>636</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 636Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15</s400><s200><s210>637</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 637Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10                  15</s400><s200><s210>638</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 638Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser1               5                   10                  15</s400><s200><s210>639</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 639Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile1               5                   10</s400><s200><s210>640</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 640Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile1               5                   10</s400><s200><s210>641</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 641Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10</s400><s200><s210>642</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 642Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg1               5                   10</s400><s200><s210>643</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 643Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile1               5                   10</s400><s200><s210>644</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 644Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile1               5                   10</s400><s200><s210>645</s210><s211>25</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 645Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro1               5                   10                  15Gln Gly Ile Val Ala Ala Trp Arg Gln            20                  25</s400><s200><s210>646</s210><s211>24</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 646Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln1               5                   10                  15Gly Ile Val Ala Ala Trp Arg Gln            20</s400><s200><s210>647</s210><s211>22</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 647Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile1               5                   10                  15Val Ala Ala Trp Arg Gln            20</s400><s200><s210>648</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 648Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln1               5                   10                  15Gly Ile Val Ala Ala            20</s400><s200><s210>649</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 649Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly1               5                   10                  15Ile Val Ala Ala            20</s400><s200><s210>650</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 650Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile1               5                   10                  15Val Ala Ala Trp            20</s400><s200><s210>651</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 651Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile1               5                   10                  15Val Ala Ala</s400><s200><s210>652</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 652Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val1               5                   10                  15Ala Ala Trp</s400><s200><s210>653</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 653Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile1               5                   10                  15Val Ala</s400><s200><s210>654</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 654Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val1               5                   10                  15Ala</s400><s200><s210>655</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 655Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala Ala1               5                   10                  15</s400><s200><s210>656</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 656Val Leu Gly Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala1               5                   10                  15</s400><s200><s210>657</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 657Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala1               5                   10</s400><s200><s210>658</s210><s211>25</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 658Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln1               5                   10                  15Pro Ile Ile Arg Ser Ile Pro Gln Gly            20                  25</s400><s200><s210>659</s210><s211>24</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 659Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln1               5                   10                  15Pro Ile Ile Arg Ser Ile Pro Gln            20</s400><s200><s210>660</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 660Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly Gln1               5                   10                  15Pro Ile Ile Arg            20</s400><s200><s210>661</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 661Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile1               5                   10                  15Pro Gln Gly</s400><s200><s210>662</s210><s211>24</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 662Leu Arg Thr Asp Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys1               5                   10                  15Leu Leu Gly Pro His Val Glu Gly            20</s400><s200><s210>663</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 663Arg Thr Asp Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu1               5                   10                  15Leu Gly Pro His Val Glu Gly            20</s400><s200><s210>664</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 664Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro1               5                   10                  15His Val Glu Gly            20</s400><s200><s210>665</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 665Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His1               5                   10                  15Val Glu Gly</s400><s200><s210>666</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 666Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val1               5                   10                  15Glu Gly</s400><s200><s210>667</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 667Thr Asp Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln1               5                   10</s400><s200><s210>668</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 668Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys1               5                   10</s400><s200><s210>669</s210><s211>24</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 669Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His1               5                   10                  15Val Glu Gly Leu Lys Ala Glu Glu            20</s400><s200><s210>670</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 670Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His1               5                   10                  15Val Glu Gly Leu Lys            20</s400><s200><s210>671</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 671Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly Pro His Val1               5                   10                  15Glu Gly Leu Lys            20</s400><s200><s210>672</s210><s211>23</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 672Leu Arg Gly Leu Leu Pro Val Leu Gly Gln Pro Ile Ile Arg Ser Ile1               5                   10                  15Pro Gln Gly Ile Val Ala Ala            20</s400><s200><s210>673</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 673Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp1               5                   10                  15Glu Leu Tyr Pro Gln            20</s400><s200><s210>674</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 674Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp1               5                   10                  15Glu</s400><s200><s210>675</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 675Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp1               5                   10                  15</s400><s200><s210>676</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 676Val Pro Pro Ser Ser Ile Trp Ala Val Arg Pro Gln Asp Leu Asp Thr1               5                   10                  15Cys Asp Pro Arg            20</s400><s200><s210>677</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 677Ile Trp Ala Val Arg Pro Gln Asp Leu Asp Thr Cys Asp Pro Arg1               5                   10                  15</s400><s200><s210>678</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 678Ala Val Arg Pro Gln Asp Leu Asp Thr Cys Asp Pro Arg1               5                   10</s400><s200><s210>679</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 679Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15Gly Gly Leu Ala            20</s400><s200><s210>680</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 680Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10                  15Gly Leu Ala</s400><s200><s210>681</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 681Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15Gly Gly Leu</s400><s200><s210>682</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 682Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10                  15Gly Leu</s400><s200><s210>683</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 683Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10                  15Leu Ala</s400><s200><s210>684</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 684Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15Gly Gly</s400><s200><s210>685</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 685Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10                  15Gly</s400><s200><s210>686</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 686Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10                  15Leu</s400><s200><s210>687</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 687Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15Gly</s400><s200><s210>688</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 688Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10                  15</s400><s200><s210>689</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 689Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15</s400><s200><s210>690</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 690Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly Leu1               5                   10                  15</s400><s200><s210>691</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 691Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu1               5                   10                  15</s400><s200><s210>692</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 692Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10                  15</s400><s200><s210>693</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 693Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala1               5                   10                  15</s400><s200><s210>694</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 694Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10</s400><s200><s210>695</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 695Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10</s400><s200><s210>696</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 696Trp Gly Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg1               5                   10</s400><s200><s210>697</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 697Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10</s400><s200><s210>698</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 698Val Arg Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala1               5                   10</s400><s200><s210>699</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 699Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10</s400><s200><s210>700</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 700Ser Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10</s400><s200><s210>701</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 701Gly Ser Leu Leu Ser Glu Ala Asp Val Arg Ala1               5                   10</s400><s200><s210>702</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 702Leu Leu Ser Glu Ala Asp Val Arg Ala Leu Gly1               5                   10</s400><s200><s210>703</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 703Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10</s400><s200><s210>704</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 704Ser Glu Ala Asp Val Arg Ala Leu Gly Gly1               5                   10</s400><s200><s210>705</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 705Glu Ala Asp Val Arg Ala Leu Gly Gly1               5</s400><s200><s210>706</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 706Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys1               5                   10                  15Asn Val Lys</s400><s200><s210>707</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 707Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys1               5                   10                  15Asn</s400><s200><s210>708</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 708Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys1               5                   10                  15</s400><s200><s210>709</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 709Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys1               5                   10                  15</s400><s200><s210>710</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 710Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln1               5                   10                  15</s400><s200><s210>711</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 711Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys1               5                   10                  15</s400><s200><s210>712</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 712Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn1               5                   10                  15</s400><s200><s210>713</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 713Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys1               5                   10</s400><s200><s210>714</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 714Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu1               5                   10                  15Asp Glu</s400><s200><s210>715</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 715Gly Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln1               5                   10                  15Lys Asn</s400><s200><s210>716</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 716Gly Leu Ser Thr Glu Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln1               5                   10                  15</s400><s200><s210>717</s210><s211>18</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 717Ile Pro Gln Gly Ile Val Ala Ala Trp Arg Gln Arg Ser Ser Arg Asp1               5                   10                  15Pro Ser</s400><s200><s210>718</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 718Gly Ile Val Ala Ala Trp Arg Gln Arg Ser Ser Arg Asp Pro Ser1               5                   10                  15</s400><s200><s210>719</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 719Ile Pro Gln Gly Ile Val Ala Ala Trp Arg Gln Arg Ser Ser Arg1               5                   10                  15</s400><s200><s210>720</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 720Ala Leu Gly Gly Leu Ala Cys Asp Leu Pro Gly Arg Phe Val Ala Glu1               5                   10                  15Ser</s400><s200><s210>721</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 721Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys Leu Ser Thr1               5                   10                  15Glu</s400><s200><s210>722</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 722Leu Lys Ala Leu Leu Glu Val Asn Lys Gly His Glu Met Ser Pro Gln1               5                   10                  15</s400><s200><s210>723</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 723Thr Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu Thr Val Ala1               5                   10                  15</s400><s200><s210>724</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 724Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu Thr Val Ala1               5                   10                  15</s400><s200><s210>725</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 725Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu Thr1               5                   10</s400><s200><s210>726</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 726Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu1               5                   10</s400><s200><s210>727</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 727Thr Leu Gly Leu Gly Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val1               5                   10                  15</s400><s200><s210>728</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 728Asp Leu Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu Leu1               5                   10                  15</s400><s200><s210>729</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 729Asp Leu Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu1               5                   10</s400><s200><s210>730</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 730Leu Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu1               5                   10</s400><s200><s210>731</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 731Asp Leu Pro Gly Arg Phe Val Ala Glu Ser Ala1               5                   10</s400><s200><s210>732</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 732Glu Arg His Arg Pro Val Arg Asp Trp Ile Leu Arg Gln Arg Gln1               5                   10                  15</s400><s200><s210>733</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 733Ser Pro Arg Gln Leu Leu Gly Phe Pro Cys Ala Glu Val Ser Gly1               5                   10                  15</s400><s200><s210>734</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 734Ser Arg Thr Leu Ala Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu1               5                   10                  15</s400><s200><s210>735</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 735Val Thr Ser Leu Glu Thr Leu Lys Ala Leu Leu Glu Val Asn Lys1               5                   10                  15</s400><s200><s210>736</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 736Leu Gly Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu1               5                   10</s400><s200><s210>737</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 737Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu1               5                   10</s400><s200><s210>738</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 738Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu1               5                   10</s400><s200><s210>739</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 739Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu Asp Leu1               5                   10</s400><s200><s210>740</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 740Ala Pro Glu Arg Gln Arg Leu Leu Pro Ala Ala Leu Ala1               5                   10</s400><s200><s210>741</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 741Phe Val Lys Ile Gln Ser Phe Leu Gly Gly Ala Pro Thr1               5                   10</s400><s200><s210>742</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 742Phe Val Lys Ile Gln Ser Phe Leu Gly Gly1               5                   10</s400><s200><s210>743</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 743Phe Val Lys Ile Gln Ser Phe Leu Gly1               5</s400><s200><s210>744</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 744Phe Leu Lys Met Ser Pro Glu Asp Ile Arg Lys1               5                   10</s400><s200><s210>745</s210><s211>21</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 745Trp Glu Leu Ser Gln Leu Thr Asn Ser Val Thr Glu Leu Gly Pro Tyr1               5                   10                  15Thr Leu Asp Arg Asp            20</s400><s200><s210>746</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 746Glu Ile Thr Ile Thr Thr Gln Thr Gly Tyr Ser Leu Ala Thr Ser Gln1               5                   10                  15Val Thr Leu Pro            20</s400><s200><s210>747</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 747Ala Thr Thr Pro Ser Trp Val Glu Thr His Ser Ile Val Ile Gln Gly1               5                   10                  15Phe Pro His</s400><s200><s210>748</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 748Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr1               5                   10                  15Val Asn Gly</s400><s200><s210>749</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 749Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu1               5                   10                  15</s400><s200><s210>750</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 750Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly1               5                   10</s400><s200><s210>751</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 751Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn1               5                   10</s400><s200><s210>752</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 752Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val1               5                   10</s400><s200><s210>753</s210><s211>12</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 753Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr1               5                   10</s400><s200><s210>754</s210><s211>11</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 754Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu1               5                   10</s400><s200><s210>755</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 755Ile Glu Leu Gly Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn1               5                   10                  15Gly</s400><s200><s210>756</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 756Leu Gly Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn Gly1               5                   10                  15</s400><s200><s210>757</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 757Leu Gly Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn1               5                   10</s400><s200><s210>758</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 758Leu Gly Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val1               5                   10</s400><s200><s210>759</s210><s211>17</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 759Glu Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn1               5                   10                  15Gly</s400><s200><s210>760</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 760Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly1               5                   10                  15</s400><s200><s210>761</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 761Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser1               5                   10                  15</s400><s200><s210>762</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 762Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr1               5                   10</s400><s200><s210>763</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 763Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu1               5                   10</s400><s200><s210>764</s210><s211>16</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 764Phe Asp Lys Ala Phe Thr Ala Ala Thr Thr Glu Val Ser Arg Thr Glu1               5                   10                  15</s400><s200><s210>765</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 765Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn1               5                   10                  15</s400><s200><s210>766</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 766Gly Leu Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu1               5                   10                  15</s400><s200><s210>767</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 767Leu Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu1               5                   10</s400><s200><s210>768</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 768Ser Asp Pro Tyr Lys Ala Thr Ser Ala Val Val Ile Thr Ser Thr1               5                   10                  15</s400><s200><s210>769</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 769Ser Asp Pro Tyr Lys Ala Thr Ser Ala Val Val Ile Thr Ser1               5                   10</s400><s200><s210>770</s210><s211>15</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 770Ser Arg Lys Phe Asn Thr Met Glu Ser Val Leu Gln Gly Leu Leu1               5                   10                  15</s400><s200><s210>771</s210><s211>13</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 771Ser Arg Lys Phe Asn Thr Met Glu Ser Val Leu Gln Gly1               5                   10</s400><s200><s210>772</s210><s211>14</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 772Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn1               5                   10</s400><s200><s210>773</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 773Ala Leu Tyr Gly Lys Leu Leu Lys Leu1               5</s400><s200><s210>774</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 774Val Tyr Val Asp Asp Ile Tyr Val Ile1               5</s400><s200><s210>775</s210><s211>10</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 775Glu Leu Ala Gly Ile Gly Ile Leu Thr Val1               5                   10</s400><s200><s210>776</s210><s211>9</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 776Tyr Leu Leu Pro Ala Ile Val His Ile1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002475A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002475</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17931596</doc-number><date>20220913</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>74</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>39</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>N</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>N</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>70539</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2863</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2818</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>39</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2851</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>92</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>94</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2318</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>622</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>505</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>31</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2319</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2319</main-group><subgroup>74</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>73</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">INSERTABLE VARIABLE FRAGMENTS OF ANTIBODIES AND MODIFIED A1-A2 DOMAINS OF NKG2D LIGANDS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>14959745</doc-number><date>20151204</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11453713</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17931596</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>62088456</doc-number><date>20141205</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>XYPHOS BIOSCIENCES INC.</orgname><address><city>South San Francisco</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>LANDGRAF</last-name><first-name>Kyle</first-name><address><city>Alameda</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Steiger</last-name><first-name>Daniel P.</first-name><address><city>San Francisco</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Williams</last-name><first-name>Steven R.</first-name><address><city>San Francisco</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Martin, JR.</last-name><first-name>David W.</first-name><address><city>Mill Valley</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>XYPHOS BIOSCIENCES INC.</orgname><role>02</role><address><city>South San Francisco</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="103.12mm" wi="105.92mm" file="US20230002475A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="97.71mm" wi="144.10mm" file="US20230002475A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="59.61mm" wi="93.73mm" file="US20230002475A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="119.72mm" wi="113.71mm" file="US20230002475A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="130.64mm" wi="155.02mm" file="US20230002475A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="110.66mm" wi="128.35mm" file="US20230002475A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="155.62mm" wi="125.31mm" file="US20230002475A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="101.85mm" wi="135.81mm" file="US20230002475A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="77.64mm" wi="171.79mm" file="US20230002475A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="113.45mm" wi="123.11mm" file="US20230002475A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="111.93mm" wi="146.13mm" file="US20230002475A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="95.17mm" wi="150.88mm" file="US20230002475A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="149.78mm" wi="139.45mm" file="US20230002475A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="97.28mm" wi="152.48mm" file="US20230002475A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="108.37mm" wi="138.35mm" file="US20230002475A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="162.56mm" wi="121.84mm" file="US20230002475A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="107.19mm" wi="123.87mm" file="US20230002475A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="123.27mm" wi="155.79mm" file="US20230002475A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="137.58mm" wi="148.17mm" file="US20230002475A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="155.70mm" wi="150.88mm" file="US20230002475A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="164.85mm" wi="121.50mm" file="US20230002475A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="152.15mm" wi="153.75mm" file="US20230002475A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="99.91mm" wi="165.10mm" file="US20230002475A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="115.82mm" wi="139.45mm" file="US20230002475A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="131.66mm" wi="158.75mm" file="US20230002475A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><p id="p-0002" num="0001">This application is a divisional of U.S. application Ser. No. 14/959,745, filed on Dec. 4, 2015 (allowed); which claims priority from U.S. Provisional Application No. 62/088,456, filed on Dec. 5, 2014 (expired).</p><p id="p-0003" num="0002">The instant application contains a Sequence Listing which has been filed electronically in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on Sep. 13, 2022, is named SEQ LIST.xml and is 140 KB in size.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">BACKGROUND OF THE INVENTION</heading><heading id="h-0002" level="1">Field of the Invention</heading><p id="p-0004" num="0003">This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands.</p><p id="p-0005" num="0004">BACKGROUND INFORMATION</p><p id="p-0006" num="0005">An antibody (Ab), <figref idref="DRAWINGS">FIG. <b>1</b></figref>, also known as an immunoglobulin (Ig), in many mammals including humans is a large, Y-shape protein used by the immune system to identify and neutralize foreign objects such as bacteria and viruses (Charles Janeway (2001). Immunobiology. (5th ed.), Chapter 3. Garland Publishing. ISBN 0-8153-3642-X. (electronic full text via NCBI Bookshelf). The antibody recognizes a unique part of the foreign target, called an antigen. Each tip of the two arms of the &#x201c;Y&#x201d; of an antibody contains an antigen binding site, or a paratope, (a structure analogous to a lock) that is specific for one particular epitope (similarly analogous to a key) of an antigen, allowing these two structures to bind together with precision.</p><p id="p-0007" num="0006">Using this binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system or can neutralize its target directly, for example, by blocking a part of a microbe that is essential for its invasion and survival. The production of antibodies is the main function of the humoral, or &#x201c;adaptive&#x201d;, immune system. Antibodies are secreted by plasma cells. Antibodies in nature can occur in two physical forms, a soluble form that is secreted from the cell, and a membrane-bound form that is attached to the surface of a B cell via the &#x201c;stem&#x201d; of the Y.</p><p id="p-0008" num="0007">Antibodies are glycoproteins belonging to the immunoglobulin superfamily and are typically made of basic structural units&#x2014;each with two large heavy chains and two small light chains. There are several different types of antibody heavy chains, and several different kinds of antibodies, which are grouped into different isotypes based on which heavy chain they possess. Five different antibody isotypes are known in mammals (Market E, Papavasiliou FN (October 2003). &#x201c;V(D)J recombination and the evolution of the adaptive immune system&#x201d;. PLoS Biol. 1 (1): E16. doi:10.1371/journal.pbio.0000016. PMC 212695. PMID 14551913). Although the general structure of all antibodies is very similar, a small region at the tip of each arm of the Y-shaped protein is extremely variable, allowing millions of antibodies with slightly different tip structures, or antigen-binding sites, to exist. This region is known as the hypervariable or variable region. Each of these natural variants can bind to a different antigen. This enormous diversity of antibodies allows the immune system to adapt and recognize an equally wide variety of antigens (Hozumi N, Tonegawa S (1976). &#x201c;Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions&#x201d;. <i>Proc. Natl. Acad. Sci. U.S.A. </i>73 (10): 3628-3632. doi:10.1073/pnas.73.10.3628. PMC 431171. PMID 824647.)</p><p id="p-0009" num="0008">The natural &#x201c;Y&#x201d;-shaped Ig molecule consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds, <figref idref="DRAWINGS">FIG. <b>1</b></figref>. Each heavy chain has two major regions, the constant region (CH) and the variable region (VH). The constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. A light chain also has two successive domains: a smaller constant region (CL) and the variable region (VL) (Woof J, Burton D (2004). &#x201c;Human antibody-Fc receptor interactions illuminated by crystal structures.&#x201d; <i>Nat Rev Immunol </i>4 (2): 89-99. doi:10.1038/nri1266. PMID 15040582).</p><p id="p-0010" num="0009">Some parts of an antibody have the same functions. Each of the two arms of the Y, for example, contains the sites that can bind to antigens and, therefore, recognize specific foreign objects. This region of the antibody is called the Fv (fragment, variable) region. It is composed of one variable domain from the heavy chain (VH) and one variable region from the light chain (VL) of the antibody(Hochman J, Inbar D, Givol D (1973). An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. <i>Biochemistry </i>12 (6): 1130-1135. doi:10.1021/bi00730&#x3b1;018. PMID 4569769). The paratope is shaped at one end of the Fv and is the region for binding to antigens. It is comprised of variable loops of (&#x3b2;-strands, three each on the VL and on the VH and is responsible for binding to the antigen, <figref idref="DRAWINGS">FIG. <b>2</b></figref>. These 6 loops are referred to as the complementarity determining regions (CDRs) (North B, Lehmann A, Dunbrack RL (2010). &#x201c;A new clustering of antibody CDR loop conformations&#x201d;. <i>J Mol Biol </i>406 (2): 228-256. doi:10.1016/j.jmb.2010.10.030. PMC 3065967. PMID 21035459).</p><p id="p-0011" num="0010">Useful polypeptides that possess specific antigen binding function can be derived from the CDRs of the variable regions of antibodies. These two antibody variable domains, one of the light chain(VL) and one from the heavy chain (VH), each with 3 CDRs can be fused in tandem, in either order, using a single, short linker peptide of 10 to about 25 amino acids to create a linear single-chain variable fragment (scFv) polypeptide comprising one each of heavy and light chain variable domains, <figref idref="DRAWINGS">FIG. <b>3</b></figref> (Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., and Whitlow, M. (1988) Single-chain antigen-binding proteins, Science 242, 423-426; Huston, J. S., Levinson, D, Mudgett-Hunter, M, Tai, M-S, Novotny, J, Margolies, M. N., Ridge, R., Bruccoleri, R E., Haber, E., Crea, R., and Opperman, H. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i>. PNAS 85: 5879-5883).</p><p id="p-0012" num="0011">The linker is usually rich in glycine for flexibility, as well as serine, threonine, or charged amino acids for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of the single linker. This format enables one ordinarily skilled in the art of recombinant DNA technology to genetically fuse the linear scFv to the N- or C-terminus of a parent protein in order to impart to the parent protein the antigen binding properties of the scFv. There are numerous other proposed or created arrangements of polyvalent and tandem scFv regions, but importantly as described below, all have at least two spatially distant termini, <figref idref="DRAWINGS">FIG. <b>4</b></figref> (Le Gall, F.; Kipriyanov, S M; Moldenhauer, G; Little, M (1999). &#x201c;Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding&#x201d;. FEBS Letters 453 (1): 164-168. doi:10.1016/50014-5793(99)00713-9. PMID 10403395).</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0013" num="0012">The present disclosure relates to modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. In some aspects, the present disclosure relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0014" num="0013">The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>1</b></figref>. A cartoon of a typical mammalian antibody showing its Y-shaped structure and structural components.</p><p id="p-0016" num="0015"><figref idref="DRAWINGS">FIG. <b>2</b></figref>. A cartoon of the structure of an Fv region of a natural mammalian antibody showing the 3 labeled (Complementarity Determining Regions) CDRs of the VH and the 3 unlabeled loops of the VL CDRs, which form the paratope or antigen binding site.</p><p id="p-0017" num="0016"><figref idref="DRAWINGS">FIG. <b>3</b></figref>. A cartoon of the two possible structures of a single-chain variable fragment (scFv), with the antigen binding sites including the N-termini on the left and the C-termini on the right. The single linker region, or linker peptide, in each scFv is shown as an arrow.</p><p id="p-0018" num="0017"><figref idref="DRAWINGS">FIG. <b>4</b></figref>. Polyvalent single-chain variable fragments (scFv's). Structure of divalent (top) and trivalent (bottom) scFvs, tandem (left) and di-/trimerization format (right). Note that each has 2 or more spatially distant free termini.</p><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIGS. <b>5</b>A and <b>5</b>B</figref>. Diagram of an insertable variable fragment, iFv. Diagram of an insertable variable fragment, iFv. <figref idref="DRAWINGS">FIG. <b>5</b>A</figref> shows the structure of variable light (VL) and variable heavy (VH) domains from FGFR3-binding antibody showing the domain topology of the iFv format. Grey arrows represent the 2 linker regions (LR), one and only one of which is used traditionally to connect the termini of VL and VH to create an scFv. The LR with a dotted border connected the C-terminus of VL to the N-terminus of VH (visible behind the molecule). The LR with a solid border connected the C-terminus of VH to the N-terminus of VL. Segments of the split VL domain are labeled Nt and Ct as described in text. As a result of the creation of non-natural pair of N- and C-termini between strand 1 (51) and strand 2 (S2) the VL has been divided into an N-terminal segment (VLN) and a C-terminal segment (VLC). The 6 CDRs of VL and VH are represented as the loops at the top of the figure. <figref idref="DRAWINGS">FIG. <b>5</b>B</figref> shows the scheme of the domain layout for inserting an iFv into loop 1 (L1) of MICA-&#x3b1;3 with or without a spacer region (SR). An iFv could also be similarly inserted into loop 2 (L2) and/or loop 3 (L3).</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>6</b></figref>. Titration curves for the modified sMICA molecules binding to FGFR3 coated wells. Bound sMICA was detected by ELISA using NKG2D-Fc to confirm the bispecific activity. Both versions of the inserted variable fragments (MICA-&#x3b1;3-iFv.1 and MICA-&#x3b1;3-iFv.2) bound FGFR3 comparably to the C-terminal fusion of an scFv (MICA-scFv).</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIGS. <b>7</b>A and <b>7</b>B</figref>. Thermal stability of MICA-&#x3b1;3-iFv.2. ELISA titration curves of MICA-scFv (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>) or MICA-&#x3b1;3-iFv.2 (<figref idref="DRAWINGS">FIG. <b>7</b>B</figref>) binding to FGFR3-coated wells after exposure to the indicated temperatures (degrees Celsius) for 1 hour. The MICA-&#x3b1;3-iFv exhibited strong binding to FGFR3 after exposure to 80&#xb0; C., whereas MICA-scFv lost significant activity after exposure to 70&#xb0; C.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>8</b></figref>. NK-mediated target cell lysis assays. NKL effector cells were co-incubated with calcein-loaded, FGFR3-expressing P815 target cells at a effector:target ratio of 15:1. Increasing concentrations of a negative control MICA (sMICA) had no effect on target cell lysis, whereas the indicated FGFR3-binding MICA-&#x3b1;3-IFv variants stimulated target cell lysis. Compared to MICA-scFv, both MICA-&#x3b1;3-iFv variants directed greater target cell lysis.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIGS. <b>9</b>A and <b>9</b>B</figref>. Target binding and cell lysis activity of a CD20-specific sMICA variant. MICA-&#x3b1;3-iFv.3 exhibited titratable binding to CD20-coated wells in an ELISA (<figref idref="DRAWINGS">FIG. <b>9</b>A</figref>), and also enhanced NK-mediated cell lysis of CD20-expressing Ramos cells (<figref idref="DRAWINGS">FIG. <b>9</b>B</figref>). In the experiments shown in <figref idref="DRAWINGS">FIG. <b>9</b>B</figref>, NKL effector cells were co-incubated with calcein-loaded CD20-expressing Ramos cells at a effector:target ratio of 15:1, and increasing concentrations of either the negative control (sMICA) or MICA-&#x3b1;3-iFv.3.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIG. <b>10</b></figref>. Titration curves for the NKG2DL-&#x3b1;3-iFv.2 proteins binding to FGFR3-coated wells. Bound protein was detected by ELISA using NKG2D-Fc to confirm the bispecific activity. All versions of the NKG2DL-&#x3b1;3-iFv.2 proteins tested (OMCP, ULBP1, 2, 3, 4, 6) bound FGFR3 similarly.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>11</b></figref>. NK-mediated target cell lysis assays. NKL effector cells were co-incubated with calcein-loaded, FGFR3-expressing P815 target cells at a effector:target ratio of 15:1. Increasing concentrations of a negative control MICA (sMICA) had no effect on target cell lysis, whereas each indicated NKG2DL-&#x3b1;3-iFv.2 protein stimulated target cell lysis.</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIGS. <b>12</b>A and <b>12</b>B</figref>. Structure-directed mutagenesis of the &#x3b1;1-&#x3b1;2 domain of MICA for enhanced NKG2D affinity. <figref idref="DRAWINGS">FIG. <b>12</b>A</figref> shows the structure of the &#x3b1;1-&#x3b1;2 domain of MICA (PDB 1HYR) with the NKG2D-binding surface mapped to 57 residues colored dark grey.</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>12</b>B</figref> shows six positions that were identified as key sites for NKG2D affinity mutations. The wild-type amino acid residues are labeled and their side chains shown in dark grey spheres.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIGS. <b>13</b>A and <b>13</b>B</figref>. NKG2D-Fc competition ELISAs to affinity rank &#x3b1;1-&#x3b1;2 variants. <figref idref="DRAWINGS">FIG. <b>13</b>A</figref> shows titration data for a panel of &#x3b1;1-&#x3b1;2 affinity variants (15-18), wild-type (WT), or WED soluble MICA proteins inhibiting human NKG2D-Fc binding to plate-coated MICA. <figref idref="DRAWINGS">FIG. <b>13</b>B</figref> shows the same set of proteins in <figref idref="DRAWINGS">FIG. <b>13</b>A</figref> titrated against mouse NKG2D-Fc. In both assays variants 15, 16, 17, and 18 display IC<sub>50 </sub>values significantly less than both WT and WED proteins. The equilibrium IC<sub>50 </sub>values are shown in Table 3.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIG. <b>14</b></figref>. Analysis of the association and dissociation kinetics for &#x3b1;1-&#x3b1;2 variants binding to NKG2D, as measured by biolayer interferometry on an Octet instrument. Kinetic traces for a panel of &#x3b1;1-&#x3b1;2 variants. The association and dissociation phases were fit using a single exponential 1:1 binding equation and on- and off-rate constants derived from the fits are shown in Table 3.</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIG. <b>15</b></figref>. NK-mediated target cell killing assay for the &#x3b1;1-&#x3b1;2 variants targeting FGFR3-expressing target cells. NKL effector cells were co-incubated with calcein-loaded, FGFR3-expressing P815 target cells at a effector:target ratio of 15:1. Increasing concentrations of a negative control MICA (sMICA) had no effect on target cell lysis, whereas the indicated &#x3b1;1-&#x3b1;2 variants stimulated target cell lysis. Relative to WT and WED-MICA, variants 16, 17, and 18 exhibited significantly increased killing at low concentrations.</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIG. <b>16</b></figref>. Analysis of the association and dissociation kinetics for &#x3b1;1-&#x3b1;2 variants 20, 25, and 48 binding to NKG2D, as measured by biolayer interferometry on an Octet instrument. The association and dissociation phases were fit using a single exponential 1:1 binding equation, and on- and off-rate constants derived from the fits are shown in Table 5,</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIG. <b>17</b></figref>. NK-mediated target cell killing, calcein-based assay for &#x3b1;1-&#x3b1;2 variants 16, 25 and WED targeting FGFR3-expressing P815 target cells.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIG. <b>18</b></figref>. Protein sequence alignment of &#x3b1;1-&#x3b1;2 domains from MICA and ULBPs (SEQ ID NOs.: 77-83). Amino acids highlighted in grey were selected for NNK mutagenesis in ULBP2 (60 amino acids) and ULBP3 (36 amino acids). Residues highlighted in black were identified as key positions for selected and identified as mutations that modulate binding affinity to NKG2D (Tables 6 and 7).</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIGS. <b>19</b>A and <b>19</b>B</figref>. Phage ELISA titrations of ULBP variants binding to NKG2D. <figref idref="DRAWINGS">FIG. <b>19</b>A</figref> depicts experiments in which ULBP2 variants displayed on phage were titrated against NKG2D and relative binding affinities were measured relative to native ULBP2 (WT, black circles). <figref idref="DRAWINGS">FIG. <b>19</b>B</figref> depicts experiments in which ULBP3 variants displayed on phage were titrated against NKG2D and relative binding affinities were measured relative to native ULBP3 (WT, black circles).</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIGS. <b>20</b>A-D</figref>. Fusions of native (WT), modified variant WED, 25 or 48 &#x3b1;1-&#x3b1;2 domains to heavy chain (<figref idref="DRAWINGS">FIG. <b>20</b>A</figref>) or light chain (<figref idref="DRAWINGS">FIG. <b>20</b>B</figref>) of an FGFR3-specific antibody affected NK-dependent target cell killing. Fusions of variants 25 and 48 to either heavy chain (<figref idref="DRAWINGS">FIG. <b>20</b>C</figref>) or light chain (<figref idref="DRAWINGS">FIG. <b>20</b>D</figref>) significantly enhanced the extent of killing and the potency of killing compared to the WED variant and to the native (WT) fusions.</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIGS. <b>21</b>A-C</figref>. Fusions of variant 25 &#x3b1;1-&#x3b1;2 domain to the heavy chains or light chains of antibodies targeting human EGFR (<figref idref="DRAWINGS">FIG. <b>21</b>A</figref>), HER2 (<figref idref="DRAWINGS">FIG. <b>21</b>B</figref>), or PDL1 (<figref idref="DRAWINGS">FIG. <b>21</b>C</figref>) each enhanced NKL cell-mediated target cell killing The poor or absent killing by the respective parent antibodies, cetuximab (<figref idref="DRAWINGS">FIG. <b>21</b>A</figref>), trastuzumab (<figref idref="DRAWINGS">FIG. <b>21</b>B</figref>), and anti-PDL1 (<figref idref="DRAWINGS">FIG. <b>21</b>C</figref>) are shown.</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIGS. <b>22</b>A and <b>22</b>B</figref>. Trastuzumab-based fusions of variant 25 &#x3b1;1-&#x3b1;2 domain arm NK cells in vivo. Parent trastuzumab, trastuzumab HC 25 fusion, and trastuzumab LC 25 fusion were conjugated with Alexa Flour. Groups of three C57BL/6 mice were injected with a single dose of 100 &#x3bc;g of parent, HC fusion or LC fusion; and blood was drawn from each animal at indicated times for plasma PK ELISAs (<figref idref="DRAWINGS">FIG. <b>22</b>A</figref>) and flow cytometric analyses of the fluorescently labeled molecules bound to peripheral NK cells (<figref idref="DRAWINGS">FIG. <b>22</b>B</figref>).</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIGS. <b>23</b>A-C</figref>. Anti-drug antibodies raised in the same animals described in Example 7 and <figref idref="DRAWINGS">FIG. <b>21</b></figref> administered Trastuzumab parent (<figref idref="DRAWINGS">FIG. <b>23</b>A</figref>),Trastuzumab-based HC (<figref idref="DRAWINGS">FIG. <b>23</b>B</figref>) and Trastuzumab-LC (<figref idref="DRAWINGS">FIG. <b>23</b>C</figref>) fusions to variant 25. The control (Ctrl) plasma was from a mouse not administered any antibody-containing agent.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIGS. <b>24</b>A and <b>24</b>B</figref>. Antibodies generated in animals administered variant 25 &#x3b1;1-&#x3b1;2 domain fusions to trastuzumab-HC and &#x2014;LC, as described in Example 7 and <figref idref="DRAWINGS">FIGS. <b>21</b>-<b>22</b></figref>, bound to both the parent antibody (<figref idref="DRAWINGS">FIG. <b>24</b>A</figref>) and to the &#x3b1;1-&#x3b1;2 domain (<figref idref="DRAWINGS">FIG. <b>24</b>B</figref>).</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIG. <b>25</b></figref>. Anti-tumor activity of an anti-PDL1 fusion to variant 25. Syngeneic MC38 tumors were implanted subcutaneously in C57BL/6 mice, and tumors grew to an average of 100 mm<sup>3 </sup>before the initiation of treatment. Upon initiation of treatment four cohorts of 10 mice per group were treated parenterally with vehicle, anti-CTLA4 (100 ug i.p.), parent anti-PDL1 (300 ug i.v.), or anti-PDL1 HC_25 fusion (300 ug i.v.) on days 1, 4, and 7. Tumor volumes (cubic mm) were measured in each animal at the indicated times.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0041" num="0040">In some aspects, the present invention relates to insertable variable fragment (iFv) peptides. Because the C-terminus and N-terminus of scFv molecules including polyvalent scFv structures are far apart spatially, scFv structures cannot be inserted into a loop region embedded within a protein fold of a parent or recipient protein without disrupting or destabilizing its fold(s) and/or without disrupting the Fv framework required to properly position the CDRs or hypervariable regions to retain their antigen-binding properties.</p><p id="p-0042" num="0041">To insert the variable fragment of an antibody containing up to 6 CDRs into one or more loop regions of a nascent parent protein molecule without disrupting structural folds of the variable fragment or of the parent protein, we invented a new class of antigen-binding peptides derived from the light and heavy chain antibody variable domains. The new structures contained two linker regions, rather than the traditional single linker of scFv structures, plus a split variable domain. Conceptually the canonical termini of the variable light (VL) and heavy (VH) domains were fused into a continuous or &#x201c;circular&#x201d; peptide. That circular peptide structure containing all 6 CDRs of the Fv can then conceptually be split at one of several possible novel sites to create an insertable Fv (iFv). The non-natural split site can be created within either the light or the heavy chain variable domain at or near the apex or turn of a loop to create new, unique N- and C-termini spatially positioned proximal to each other, preferably within 0.5 to 1.5 nm, so as to be insertable into loops of other (parent or recipient) proteins or polypeptides without disrupting the structure, stability, or desirable function. This new class of peptides is called an insertable variable fragment (iFv). The binding or targeting specificity conveyed by an iFv to a recipient molecule can be changed by inserting into the recipient another or different iFV based on a different antibody or scFv or by replacing 1 or more of the CDRs of an existing insertable iFv.</p><p id="p-0043" num="0042">The insertion of one or more iFv polypeptides exhibiting specific antigen-binding properties of Fv domains into other proteins and thereby imparting novel binding properties will have multiple utilities. Such uses include but are not limited to enabling the parent protein to bind the specific antigen, target the antigen, detect the presence of antigen, remove the antigen, contact or draw near the antigen, to deliver a payload to the antigen or antigen-expressing cell, recruit the antigen, and image the presence of the antigen. A payload could be conjugated directly to one or both the amino-terminus and carboxy-terminus of an iFv or indirectly to an iFv via a parent protein or peptide. Examples of payloads include but are not limited to a chromophore, a fluorophore, a pharmacophore, an atom, a heavy or radioactive isotope, an imaging agent, a chemotherapeutic agent, or a toxin. A payloaded iFv can be used to locate or identify the presence of a target molecule to which the iFv specifically binds and as such can serve as in vitro or in vivo imaging agents or diagnostic agents that are small and stable. In addition, to one or both the amino-terminus and carboxy-terminus of an iFv peptide a chemotherapeutic agent or toxic molecule can be conjugated in order to create an iFv-drug conjugate, for example, as treatment for a malignancy or infection. A single payload may be conjugated to both the amino-terminus and the carboxy-terminus of an iFv peptide so as to span or connect the two termini; such spanning may further stabilize the iFv by blocking the termini from exopeptidase degradation or protecting the iFv from denaturation or unfolding.</p><p id="p-0044" num="0043">Examples of parent or recipient proteins or polypeptides that are candidates for insertions of iFv peptides include but are not limited to antibodies, proteins comprised of Ig folds or Ig domains, globulins, albumens, fibronectins and fibronectin domains, integrins, fluorescent proteins, enzymes, outer membrane proteins, receptor proteins, T-cell receptors, chimeric antigen receptors, viral antigens, virus capsids, viral ligands for cell receptors, high molecular weight bacteriocins, histones, hormones, knottins, cyclic peptides or polypeptides, major histocompatibility (MHC) family proteins, MIC proteins, lectins, and ligands for lectins. It is also possible to insert iFv structures into non-protein recipient molecules such a polysaccharides, dendrimers, polyglycols, peptidoglycans, antibiotics, and polyketides.</p><p id="p-0045" num="0044">Natural killer (NK) cells and certain (CD8+ &#x3b1;&#x3b2; and &#x3b3;&#x3b4;) T-cells of the immunity system have important roles in humans and other mammals as first-line, innate defense against neoplastic and virus-infected cells (Cerwenka, A., and L.L. Lanier. 2001. NK cells, viruses and cancer. Nat. Rev. Immunol. 1:41-49). NK cells and certain T-cells exhibit on their surfaces NKG2D, a prominent, homodimeric, surface immunoreceptor responsible for recognizing a target cell and activating the innate defense against the pathologic cell (Lanier, LL, 1998. NK cell receptors. Ann. Rev. Immunol. 16: 359-393; Houchins JP et al. 1991. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human NK cells. J. Exp. Med. 173: 1017-1020; Bauer, S et al., 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-730). The human NKG2D molecule possesses a C-type lectin-like extracellular domain that binds to its cognate ligands, the 84% sequence identical or homologous, monomeric MICA and MICB, polymorphic analogs of the Major Histocompatibility Complex (MHC) Class I chain-related glycoproteins (MIC) (Weis et al. 1998. The C-type lectin superfamily of the immune system. Immunol. Rev. 163: 19-34; Bahram et al. 1994. A second lineage of mammalian MHC class I genes. PNAS 91:6259-6263; Bahram et al. 1996a. Nucleotide sequence of the human MHC class I MICA gene. Immunogenetics 44: 80-81; Bahram and Spies TA. 1996. Nucleotide sequence of human MHC class I MICB cDNA. Immunogenetics 43: 230-233). Non-pathologic expression of MICA and MICB is restricted to intestinal epithelium, keratinocytes, endothelial cells and monocytes, but aberrant surface expression of these MIC proteins occurs in response to many types of cellular stress such as proliferation, oxidation and heat shock and marks the cell as pathologic (Groh et al. 1996. Cell stress-regulated human MHC class I gene expressed in GI epithelium. PNAS 93: 12445-12450; Groh et al. 1998. Recognition of stress-induced MHC molecules by intestinal &#x3b3;&#x3b4;T cells. Science 279: 1737-1740; Zwirner et al. 1999. Differential expression of MICA by endothelial cells, fibroblasts, keratinocytes and monocytes. Human Immunol. 60: 323-330). Pathologic expression of MIC proteins also seems involved in some autoimmune diseases (Ravetch, J V and Lanier L L. 2000. Immune Inhibitory Receptors. Science 290: 84-89; Burgess, S J. 2008. Immunol. Res. 40: 18-34). The differential regulation of NKG2D ligands, such as the polymorphic MICA and MICB, is important to provide the immunity system with a means to identify and respond to a broad range of emergency cues while still protecting healthy cells from unwanted attack (Stephens H A, (2001) MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol. 22: 378-85; Spies, T. 2008. Regulation of NKG2D ligands: a purposeful but delicate affair. Nature Immunol. 9: 1013-1015).</p><p id="p-0046" num="0045">Viral infection is a common inducer of MIC protein expression and identifies the viral-infected cell for NK or T-cell attack (Groh et al. 1998; Groh et al. 2001. Co-stimulation of CD8+ &#x3b1;&#x3b2;T-cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2: 255-260; Cerwenka, A., and L. L. Lanier. 2001). In fact, to avoid such an attack on its host cell, cytomegalovirus and other viruses have evolved mechanisms that prevent the expression of MIC proteins on the surface of the cell they infect in order to escape the wrath of the innate immunity system (Lodoen, M., K. Ogasawara, J.A. Hamerman, H. Arase, J.P. Houchins, E.S. Mocarski, and L.L. Lanier. 2003. NKG2D-mediated NK cell protection against cytomegalovirus is impaired by gp40 modulation of RAE-1 molecules. J. Exp. Med. 197:1245-1253; Stern-Ginossar et al., (2007) Host immune system gene targeting by viral miRNA. Science 317: 376-381; Stern-Ginossar et al., (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nature Immunology 9: 1065-73; Slavuljica, I A Busche, M Babic , M Mitrovic, I Gas&#x306;parovic, D Cekinovic, E Markova Car, EP Pugel, A Cikovic, VJ Lisnic, WJ Britt, U Koszinowski, M Messerle, A Krmpotic and S Jonjic. 2010. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J. Clin. Invest. 120: 4532-4545).</p><p id="p-0047" num="0046">In spite of their stress, many malignant cells, such as those of lung cancer and glioblastoma brain cancer, also avoid the expression of MIC proteins and as a result may be particularly aggressive as they too escape the innate immunity system (Busche, A et al. 2006, NK cell mediated rejection of experimental human lung cancer by genetic over expression of MEW class I chain-related gene A. Human Gene Therapy 17: 135-146; Doubrovina, E S, M M Doubrovin, E Vider, R B Sisson, R J O'Reilly, B Dupont, and Y M Vyas, 2003. Evasion from N K Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma (2003) J. Immunology 6891-99; Friese, M. et al. 2003. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research 63: 8996-9006; Fuertes, M B, M V Girart, L L Molinero, C I Domaica, L E Rossi, M M Barrio, J Mordoh, G A Rabinovich and N W Zwirner. (2008) Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity. J. Immunology, 180: 4606 -4614).</p><p id="p-0048" num="0047">The high resolution structure of human MICA bound to NKG2D has been solved and demonstrates that the &#x3b1;3 domain of MICA has no direct interaction with the NKG2D (Li et al. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nature Immunol. 2: 443-451; Protein Data Bank accession code 1HYR). The &#x3b1;3 domain of MICA, like that of MICB, is connected to the &#x3b1;1-&#x3b1;2 platform domain by a short, flexible linker peptide, and itself is positioned naturally as &#x201c;spacer&#x201d; between the platform and the surface of the MIC expressing cell. The 3-dimensional structures of the human MICA and MICB &#x3b1;3 domains are nearly identical (root-mean square distance &#x3c;1 A on 94 C-aa's) and functionally interchangeable (Holmes et al. 2001. Structural Studies of Allelic Diversity of the MHC Class I Homolog MICB, a Stress-Inducible Ligand for the Activating Immunoreceptor NKG2D. J Immunol. 169: 1395-1400).</p><p id="p-0049" num="0048">As used herein, a &#x201c;soluble MIC protein&#x201d;, &#x201c;soluble MICA&#x201d; and &#x201c;soluble MICB&#x201d; refer to a MIC protein containing the &#x3b1;1, &#x3b1;2, and &#x3b1;3 domains of the MIC protein but without the transmembrane or intracellular domains.</p><p id="p-0050" num="0049">The &#x3b1;1-&#x3b1;2 platform domain of a soluble MIC protein is tethered to the &#x3b1;3 domain and is diffusible in the intercellular or intravascular space of the mammal. Preferably the &#x3b1;1-&#x3b1;2 platform domains of the non-natural MIC proteins of the invention are at least 80% identical or homologous to a native or natural &#x3b1;1-&#x3b1;2 domain of a human MICA or MICB protein and bind NKG2D. In some embodiments, the &#x3b1;1-&#x3b1;2 platform domain is 85% identical to a native or natural &#x3b1;1-&#x3b1;2 platform domain of a human MICA or MICB protein and binds NKG2D. In other embodiments, the &#x3b1;1-&#x3b1;2 platform domain is 90%, 95%, 96%, 97%, 98%, or 99% identical to a native or natural &#x3b1;1-&#x3b1;2 platform domain of a human MICA or MICB protein and binds NKG2D.</p><p id="p-0051" num="0050">In some embodiments, a heterologous peptide tag may be fused to the N-terminus or C-terminus of an &#x3b1;1-&#x3b1;2 domain or a soluble MIC protein to aid in the purification of the soluble MIC protein. Tag sequences include peptides such as a poly-histidine, myc-peptide or a FLAG tag. Such tags may be removed after isolation of the MIC molecule by methods known to one skilled in the art.</p><p id="p-0052" num="0051">As used herein &#x201c;peptide&#x201d;, &#x201c;polypeptide&#x201d;, and &#x201c;protein&#x201d; are used interchangeably; and a &#x201c;heterologous molecule&#x201d;, &#x201c;heterologous peptide&#x201d;, &#x201c;heterologous sequence&#x201d; or &#x201c;heterologous atom&#x201d; is a molecule, peptide, nucleic acid or amino acid sequence, or atom, respectively, that is not naturally or normally found in physical conjunction with the subject molecule.</p><p id="p-0053" num="0052">The term &#x201c;comprising,&#x201d; which is used interchangeably with &#x201c;including,&#x201d; &#x201c;containing,&#x201d; or &#x201c;characterized by,&#x201d; is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase &#x201c;consisting of&#x201d; excludes any element, step, or ingredient not specified in the claim. The phrase &#x201c;consisting essentially of&#x201d; limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.</p><p id="p-0054" num="0053">All references cited herein are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not. As used herein, the terms &#x201c;a&#x201d;, &#x201c;an&#x201d;, and &#x201c;any&#x201d; are each intended to include both the singular and plural forms.</p><p id="p-0055" num="0054">Having now fully described the invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.</p><heading id="h-0006" level="1">EXAMPLES of iFv and of Modified al- &#x3b1;2 Domains of NKG2D Ligands</heading><p id="p-0056" num="0055">Example 1 (iFv). As specific examples, we synthesized a 1126 bp and a 1144 bp DNA fragment (SEQ ID NO:1 and 2, respectively) encoding in the following order: the &#x3b1;3 domain of human MICA (as a parent peptide) amino acid 182 to amino acid 194 (the beginning of loop 1 of the &#x3b1;3 domain), no spacer or a GGS amino acid spacer region (SR), an iFv peptide based on the structure of a Fibroblast Growth Factor Receptor 3 (FGFR3)-binding antibody (MAbR3;Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., Ross, S., Stinson, S., Dornan, D., French, D., Wang, Q. R., Stephan, J. P., Wu, Y., Wiesmann, C., and Ashkenazi, A. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice, <i>The Journal of clinical investigation </i>119, 1216-1229.), no spacer or another GGS spacer region, the distal portion of loop 1 of the &#x3b1;3 domain starting at amino acid 196 and including the remaining carboxy-terminal portion of the &#x3b1;3 domain to amino acid 276 of a soluble MICA molecule. Each synthetic, double stranded DNA polynucleotide then encoded a polypeptide that contained 6 CDRs in the form of an iFv inserted into loop 1 of the &#x3b1;3 domain of MICA.</p><p id="p-0057" num="0056">This iFv peptide itself (SEQ ID NO.:3), encoded by SEQ ID NO.:4, contained two identical, typical linker regions (LR) corresponding to residues GGSSRSSSSGGGGSGGGG (SEQ ID NO.:5) (Andris-Widhopf, J., Steinberger, P., Fuller, R., Rader, C., and Barbas, C. F., 3rd. (2011) Generation of human Fab antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences, Cold Spring Harbor protocols 2011). One LR joined the C-terminus of VL to the N-terminus of the VH domain, and the second LR joined the C-terminus of the VH domain to the N-terminus of VL. Conceptually this new structure is the continuous or &#x201c;circular&#x201d; peptide referred to above and contained 6 CDRs of the starting Fv. The variable VL chain of the antibody was effectively split within the loop region between beta-strands 1 and 2 (51 and S2) and thereby created a new N-terminal segment (VLN) and a new C-terminal segment (VLC) with an accompanying pair of new, non-natural C- and N-termini, respectively, <figref idref="DRAWINGS">FIG. <b>5</b>A</figref>. This pair of termini created a sole site for attachment or conjugation of the iFv to the recipient molecule such as a protein. The schematic of the inserted iFv in the parent &#x3b1;3 domain is shown in <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>.</p><p id="p-0058" num="0057">To produce the soluble MICA proteins with a heterologous iFv peptide inserted into the &#x3b1;3 domain we generated a baculoviral expression vector to accommodate the DNA sequences (SEQ ID NO.s:1 and 2) encoding the &#x3b1;3-iFv.1 (SEQ ID NO.:6) and &#x3b1;3-iFv.2 (SEQ ID NO.:7), respectively. The DNA fragments were amplified by PCR, digested using Ncol and EcoRI restriction enzymes, and subcloned into the baculoviral expression vector, SW403, replacing the wild-type &#x3b1;3 domain. SW403 is a baculoviral expression vector derived from pVL1393 (Invitrogen, Inc.) into which wild-type sMICA (residues 1-276) had previously been cloned using 5&#x2032; BamHI and 3&#x2032; EcoRI sites. The new expression vector was co-transfected with baculoviral DNA into SF9 insect cells, and baculovirus was grown for two amplification cycles and used to express the His-tagged MICA-&#x3b1;3-IFv proteins in T.ni insect cells according to manufacturer's protocol (Invitrogen). The expression was carried out in a 100 mL volume for three days and the growth medium was harvested for purification of the secreted soluble protein using Ni-affinity chromatography. Monomeric MICA-&#x3b1;3-IFv was purified to &#x3e;90% purity with the expected molecular weight of 60.9 kDa as determined by SDS-PAGE. Functional characterization was carried out using binding ELISAs and in vitro target cell killing assays.</p><p id="p-0059" num="0058">The purified MICA-&#x3b1;3-IFv proteins were tested in a FGFR3-binding ELISA to confirm simultaneous binding to the FGFR3 target and the NKG2D receptor. FGFR3 in phosphate buffered saline (PBS) was coated onto Maxisorp plates at 2 ug/ml concentration. Each MICA protein was titrated, allowed to bind FGFR3 for 1 hour, and washed to remove unbound sMICA protein. Bound MICA-&#x3b1;3-IFv protein was detected using NKG2D-Fc and anti-Fc-HRP conjugate. <figref idref="DRAWINGS">FIG. <b>6</b></figref> shows that the binding of both MICA-&#x3b1;3-iFv.1 and MICA-&#x3b1;3-iFv.2 to FGFR3 was comparable to that of a MICA-scFv, made by fusing to the C-terminus of soluble MICA a traditional scFv constructed from MAbR3. These ELISA results also indicated that both the FGFR3 and NKG2D binding specificities of the scFv and the &#x3b1;1-&#x3b1;2 domain, respectively, were retained by the modified MICA and demonstrated that the iFv peptide inserted using different spacer formats was functional.</p><p id="p-0060" num="0059">We tested and compared the thermal stability of sMICA-&#x3b1;3-iFv.2 to that of sMICA-scFv. Both proteins were subjected for 1 hr to increasing temperatures from 60-90 &#xb0; C. and then allowed to equilibrate to room temperature for 1 hour before being assayed for binding properties by ELISA. The results in <figref idref="DRAWINGS">FIGS. <b>7</b>A and <b>7</b>B</figref> showed that MICA-&#x3b1;3-iFv.2 can be subjected to temperatures as high as 80&#xb0; C. with no loss in specific binding to FGFR3. The traditional MICA-scFv lost binding activity at 70&#xb0; C. This result indicated that soluble MICA containing the invented iFv format is significantly more stable than terminal fusions of a traditional scFv (Miller, B. R., Demarest, S. J., Lugovskoy, A., Huang, F., Wu, X., Snyder, W. B., Croner, L. J., Wang, N., Amatucci, A., Michaelson, J. S., and Glaser, S. M. (2010) Stability engineering of scFvs for the development of bispecific and multivalent antibodies, Protein engineering, design &#x26; selection : PEDS 23, 549-557; Weatherill, E. E., Cain, K. L., Heywood, S. P., Compson, J. E., Heads, J. T., Adams, R., and Humphreys, D. P. (2012) Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation, Protein engineering, design &#x26; selection : PEDS 25, 321-329).</p><p id="p-0061" num="0060">The ability of MICA-&#x3b1;3-iFv to redirect NK cell-mediated lysis of FGFR3-expressing target cells was demonstrated in vitro in a calcein-release assay. The Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded P815 target cells ectopically expressing FGFR3. The results in <figref idref="DRAWINGS">FIG. <b>8</b></figref> showed that the two MICA-&#x3b1;3-iFv molecules induced significantly greater NK-mediated lysis compared to the traditional MICA-scFv fusion, while the non-targeted soluble MICA control had no killing activity. These results confirmed that the invented iFv bound FGFR3 on target cells and in the context of the complete parent protein molecule, soluble MICA, induced potent NK cell-mediated lysis.</p><p id="p-0062" num="0061">The applicability of the iFv format to other antibody variable domains was demonstrated by similarly constructing an &#x3b1;3-iFv.3 (SEQ ID NO.:8), which contained an iFv derived from a CD20-specific antibody (Du, J., Wang, H., Zhong, C., Peng, B., Zhang, M., Li, B., Huo, S., Guo, Y., and Ding, J. (2007) Structural basis for recognition of CD20 by therapeutic antibody Rituximab, The Journal of biological chemistry 282, 15073-15080). <figref idref="DRAWINGS">FIGS. <b>9</b>A and <b>9</b>B</figref> show that MICA-&#x3b1;3-iFv.3 was able to specifically bind wells coated with CD20 in a plate-based</p><p id="p-0063" num="0062">ELISA as described above and also induced NK-mediated lysis of Ramos cells expressing CD20 in a calcein-release assay.</p><p id="p-0064" num="0063">Example 2 (Modified al- &#x3b1;2 Domains of NKG2D Ligands). Human proteins designated ULBP-1 through ULBP-6 are, like MICA and MICB, naturally occurring, stress-induced, cell surface ligands that bind NKG2D receptors on and activate human NK cells and certain T-cells (15; Cerwenka A, Lanier LL (2004). NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61 (5): 335-43. doi:10.1034/j.1399-0039.2003.00070.x. PMID 12753652). In addition, the cowpox virus protein OMCP is a secreted domain that like the &#x3b1;1-&#x3b1;2 domain of MIC proteins binds NKG2D. OMCP exhibits a very high affinity for NKG2D, apparently in order to block NKG2D&#x2032;s recognition of the natural stress ligands induced by the virus on its infected host cell (Eric Lazear, Lance W. Peterson, Chris A. Nelson, David H. Fremont. J Virol. 2013 January; 87(2): 840-850. doi: 10.1128/JVI.01948-12). While the ULBPs and OMCP are considered NKG2D ligands (NKG2DLs) that share the canonical &#x3b1;1-&#x3b1;2 domain structure, the sequence homology with MICA &#x3b1;1-&#x3b1;2 is less than 27%, and they all naturally lack an &#x3b1;3 domain for tethering targeting domains. We constructed a series of non-natural ULB and OMCP proteins by attaching the heterologous polypeptides that specifically targeted and killed FGFR3-expressing cells as the result of fusing to each of ULBP-1, ULBP-2, ULBP-3, ULBP-4, ULBP-6 and OMCP, a modified &#x3b1;3 domain of MICA into which a targeting iFv had been inserted. In addition, we modified the &#x3b1;1-&#x3b1;2 domain of MICA to enhance the affinity of &#x3b1;1-&#x3b1;2 domain for NKG2D and then attached to the modified &#x3b1;1-&#x3b1;2 domains heterologous molecules such as polypeptides. To produce the proteins consisting of ULBP and OMCP &#x3b1;1-&#x3b1;2 domains attached to modified &#x3b1;3-IFv domains we generated a baculoviral expression vector to accommodate the DNA fragments</p><p id="p-0065" num="0064">(SEQ ID NOs:9-14) that encoded the different &#x3b1;1-&#x3b1;2 domains of ULBP-1, ULBP-2, ULBP-3, ULBP-4, ULBP-6, and OMCP (SEQ ID NOs:15-20, respectively). The DNA fragments were amplified by PCR, digested using BlpI and Ncol restriction enzymes, and individually subcloned into the baculoviral expression vector, KLM44, replacing the MICA &#x3b1;1-&#x3b1;2 domain. KLM44 was a baculoviral expression vector derived from SW403 into which MICA-&#x3b1;3-iFv.2 had previously been cloned (example 1). The new NKG2DL-&#x3b1;3-iFv.2 constructs, containing the ULBPs and OMCP &#x3b1;1-&#x3b1;2 domain fusions to &#x3b1;3-iFv.2 (ULBP1-&#x3b1;3-iFv.2, ULBP2-&#x3b1;3-iFv.2, ULBP3-&#x3b1;3-iFv.2, ULBP4-&#x3b1;3-iFv.2, ULBP6-&#x3b1;3-iFv.2, and OMCP-&#x3b1;3-iFv.2; SEQ ID NO.:21-26, respectively), were co-transfected with baculoviral DNA into SF9 insect cells. Baculovirus was grown for two amplification cycles and used to express these His-tagged NKG2DL-&#x3b1;3-iFv.2 proteins in T.ni insect cells according to manufacturer's protocol (Invitrogen). The expression was carried out in a 100 mL volume for three days and the growth medium was harvested for purification of the secreted soluble protein using Ni-affinity chromatography. Monomeric proteins of correct molecular weight were purified to &#x3e;90% purity as determined by SDS-PAGE. Functional characterization was carried out using binding ELISAs and in vitro target cell killing assays.</p><p id="p-0066" num="0065">The 6 purified NKG2DL-&#x3b1;3-iFv.2 proteins were tested in a FGFR3-binding ELISA to confirm simultaneous binding to the FGFR3 target and the NKG2D receptor. FGFR3 in phosphate buffered saline (PBS) was coated onto Maxisorp plates at 2 ug/ml concentration. Each NKG2DL-&#x3b1;3-iFv.2 protein was titrated, allowed to bind FGFR3 for 1 hour, and washed to remove unbound protein. The bound NKG2DL-&#x3b1;3-iFv.2 protein was detected using NKG2D-Fc and anti-Fc-HRP conjugate. <figref idref="DRAWINGS">FIG. <b>10</b></figref> shows that all 6 NKG2DL-&#x3b1;3-iFv.2 proteins bound potently to FGFR3, as expected, through interaction with the iFv.2 domain, and the NKG2D binding activity was retained by the attached NKG2DL &#x3b1;1-&#x3b1;2 domains, which demonstrated that the attached &#x3b1;3-IFv domain imparted functional FGFR3 binding activity to the ULBP and OMPC proteins that, like MIC proteins, bind NKG2D.</p><p id="p-0067" num="0066">The ability of the NKG2DL-&#x3b1;3-iFv.2 proteins to redirect NK cell-mediated lysis of FGFR3-expressing target cells was demonstrated in vitro in a calcein-release assay. The Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded P815 target cells ectopically expressing FGFR3. The results in <figref idref="DRAWINGS">FIG. <b>11</b></figref> showed that OMCP-&#x3b1;3-iFv.2 induced the greatest NK-mediated lysis, while the other NKG2DL-&#x3b1;3-iFv.2 proteins all displayed specific killing activity with varying degrees of potency and amount of lysis. These results confirmed that the invented iFv imparts specific binding activity to other proteins that retained their own functional properties and induced different levels of cell-mediated lysis of iFv-targeted cells.</p><p id="p-0068" num="0067">Example 3 (Modified &#x3b1;1-&#x3b1;2 Domains of NKG2D Ligands). These are examples of attaching polypeptides to NKG2DLs which were modified to significantly enhance their binding affinity to the human NKG2D receptor. The &#x3b1;1-&#x3b1;2 domain of MIC proteins is an NKG2DL for the NKG2D receptor. This affinity is sufficient for physiologic activation of NK cells and stimulating lysis of cells expressing native full-length MIC proteins irreversibly tethered to the two-dimensional plasma membrane surface of a &#x201c;target cell&#x201d; (Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T., Science. 1999 Jul 30;285(5428):727-9.). However, because engineered soluble MIC proteins of the instant invention reversibly bind specific target antigens on the surface of a target cell, the binding affinity of the engineered soluble MIC protein to NKG2D will directly affect the stability of the soluble MIC-dependent complex formed between NK cells and cells expressing target antigens. Especially if the affinity between sMICA and NKG2D is increased by a substantially slower dissociation rate or off-rate of the modified sMICA from NKG2D, the NK cell-based killing would be expected to be greater at lower densities of soluble MIC molecules bound to a target cell. Prior to the instant invention there had not been identified any &#x3b1;1-&#x3b1;2 mutations that alter the killing activity of soluble MIC proteins or significantly reduce the binding off-rate to enhance affinity of MIC proteins to NKG2D. A computational design effort showed that three mutations in the &#x3b1;1-&#x3b1;2 domain of wild-type MICA: N69W, K152E, and K154D (WED-MICA) in combination can moderately affect NKG2D binding affinity by affecting the stability of unbound MICA and thereby its association rate or on-rate of binding to NKG2D (Lengyel CS, Willis LJ, Mann P, Baker D, Kortemme T, Strong RK, McFarland BJ.J Biol Chem. 2007 Oct 19;282(42):30658-66. Epub 2007 Aug 8); Subsequent extensive computational design work by the same group scanning by iterative calculations 22 amino acid positions of MICA theoretically in contact with NKG2D, according to the published structural descriptions (Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK., Nat Immunol. 2001 May;2(5):443-451), showed experimentally that when combined with the earlier designed 3 changes, further rational, iterative computational design of MICA qualitatively changed its affinity for NKG2D from weak (Kd &#x2dc;2.5 &#x3bc;M) to moderately tight (Kd 51 nM) <sup>-</sup>with a total of seven combined mutations (1-lenager, Samuel Melissa A. Hale, Nicholas J. Maurice, Erin C. Dunnington, Carter J. Swanson, Megan J. Peterson, Joseph J. Ban, David. J. Culpepper, Luke D. Davies, Lisa K. Sanders, and Benjamin J. McFarland, 2102, Combining different design strategies for rational affinity maturation of the MICA-NKG2D interface. Protein Science 21:1396-1407). In contrast, the experimental approach described in the instant invention experimentally selected amino acid modifications of MICA that slowed the off-rate between the &#x3b1;1-&#x3b1;2 domain of MICA and NKG2D, commencing with a MICA stabilized.</p><p id="p-0069" num="0068">by the 3 WED changes of Lengyel et al (Lengyel CS, Willis L J, Mann P, Baker D, Kortemme T, Strong R K, McFarland B J., J Biol Chem. 2007 Oct. 19; 282(42):30658-66. Epub 2007 Aug 8).</p><p id="p-0070" num="0069">This example of the instant invention relates to modifying the NKG2D binding affinity of soluble MIC proteins through engineering specific mutations at selected amino acid positions within the &#x3b1;1-&#x3b1;2 domain that influence the off-rate binding kinetics and thereby alter the NK cell-mediated killing activity of the invented non-natural, targeted MIC molecules.</p><p id="p-0071" num="0070">To engineer soluble non-natural &#x3b1;1-&#x3b1;2 domains with altered affinity to NKG2D 57 residues in the &#x3b1;1-&#x3b1;2 domain were chosen for extensive mutagenesis (<figref idref="DRAWINGS">FIG. <b>12</b>A</figref>). Synthetic DNA libraries coding for the &#x3b1;1-&#x3b1;2 domain and containing NNK mutagenic codons at each of the 57 amino acid positions were synthesized, individually cloned as fusions to the pIII minor coat protein of M13 phage, and phage particles displaying the mutagenized &#x3b1;1-&#x3b1;2 variants were produced in SS320 <i>E.coli </i>cells according to standard methodologies (Andris-Widhopf, J., Steinberger, P., Fuller, R., Rader, C., and Barbas, C. F., 3rd. (2011) Generation of human Fab antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences, Cold Spring Harbor protocols 2011). The &#x3b1;1-&#x3b1;2 phage libraries were sorted for increased binding affinity using recombinant biotinylated NKG2D as the target antigen and cycled through iterative rounds of intentionally prolonged binding, prolonged washing, and eluting of the phage clones in order to select high affinity variants enriched for slow dissociation- or off-rates. A set of specific amino acid mutations occurred at high frequencies at 6 positions in &#x3b1;1-&#x3b1;2 and were selected as preferred amino acid substitutions with enhanced NKG2D binding affinity (<figref idref="DRAWINGS">FIG. <b>12</b>B</figref>, Table 1).</p><p id="p-0072" num="0071">Table 1. Selected affinity mutations at the indicated 6 amino acid positions of the &#x3b1;1-&#x3b1;2 domain of MIC. The amino acids of SEQ ID NOs.: 35 at each of the 6 positions are shown in bold in the first row of the table. The identified affinity mutations are listed in decreasing frequency from top to bottom. All amino acids are represented by the single letter IUPAC abbreviations.</p><p id="p-0073" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><colspec colname="6" colwidth="35pt" align="left"/><thead><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>S20</entry><entry>G68</entry><entry>K125</entry><entry>E152</entry><entry>H161</entry><entry>Q166</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>P</entry><entry>L</entry><entry>L</entry><entry>T</entry><entry>R</entry><entry>F</entry></row><row><entry>T</entry><entry>F</entry><entry>R</entry><entry>V</entry><entry>S</entry><entry>S</entry></row><row><entry>D</entry><entry>S</entry><entry>F</entry><entry>G</entry><entry>A</entry><entry>H</entry></row><row><entry>A</entry><entry>A</entry><entry>T</entry><entry>F</entry><entry>K</entry><entry>Y</entry></row><row><entry>L</entry><entry>Y</entry><entry>A</entry><entry>Y</entry><entry>G</entry><entry>W</entry></row><row><entry>N</entry><entry>I</entry><entry>N</entry><entry>A</entry><entry>L</entry><entry>V</entry></row><row><entry/><entry>E</entry><entry>V</entry><entry>Q</entry><entry>F</entry><entry>L</entry></row><row><entry/><entry>T</entry><entry>Y</entry><entry>D</entry><entry>Y</entry><entry>M</entry></row><row><entry/><entry>W</entry><entry>I</entry><entry>I</entry><entry/><entry/></row><row><entry/><entry/><entry>S</entry><entry>N</entry><entry/><entry/></row><row><entry/><entry/><entry/><entry>S</entry><entry/><entry/></row><row><entry/><entry/><entry/><entry>H</entry><entry/><entry/></row><row><entry/><entry/><entry/><entry>M</entry><entry/><entry/></row><row><entry/><entry/><entry/><entry>P</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0074" num="0072">We synthesized DNA polynucleotides (SEQ ID NOs. 27-30) encoding the &#x3b1;1-&#x3b1;2 domains of 4 representative variants 15, 16, 17, 18 that contained different combinations of specific discovered mutations (Table 2).</p><p id="p-0075" num="0073">Table 2. Sequences of specific &#x3b1;1-&#x3b1;2 domain variants. The specific amino acid substitutions for variants 15, 16, 17, and 18 (SEQ ID NOS.: 31-34, respectively) are listed relative to the amino acids of SEQ ID NO.:35 in bold. All amino acids are represented by the single letter IUPAC abbreviations.</p><p id="p-0076" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="28pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row><row><entry/><entry>Variant</entry><entry>SEQ ID NO.:</entry><entry>S20</entry><entry>G68</entry><entry>K125</entry><entry>H161</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>15</entry><entry>31</entry><entry>S</entry><entry>G</entry><entry>N</entry><entry>R</entry></row><row><entry/><entry>16</entry><entry>32</entry><entry>S</entry><entry>G</entry><entry>L</entry><entry>R</entry></row><row><entry/><entry>17</entry><entry>33</entry><entry>S</entry><entry>L</entry><entry>L</entry><entry>R</entry></row><row><entry/><entry>18</entry><entry>34</entry><entry>p</entry><entry>L</entry><entry>L</entry><entry>R</entry></row><row><entry/><entry namest="offset" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0077" num="0074">To the NKG2DLs in the above example, we directly attached heterologous molecules such as a polypeptide to each of these 4 modified &#x3b1;1-&#x3b1;2 NKG2DLs using a linker peptide. Four His-tagged proteins (SEQ ID NOs.: 31-34) consisting of modified NKG2DLs with attached heterologous molecules were expressed in insect cells and purified to characterize their NKG2D binding affinities and kinetic binding parameters. Using a competitive binding ELISA, we determined the relative NKG2D binding affinities of the 4 modified &#x3b1;1-&#x3b1;2 variants. A soluble wild type (WT) NKG2DL, sMICA protein, was coated in all wells of a maxisorp ELISA plate to provide a binding partner for the human NKG2D-Fc reagent. Solutions of the four &#x3b1;1-&#x3b1;2 variants as well as WT and WED- &#x3b1;1-&#x3b1;2 domains (SEQ ID NO.: 35) were titrated in the ELISA wells and allowed to competitively inhibit 2nM human NKG2D-Fc binding to the WT sMICA coated on the plate. The level of human NKG2D-Fc that bound to the WT NKG2DL on the plate was detected using an anti-Fc-HRP antibody. <figref idref="DRAWINGS">FIG. <b>13</b>A</figref> shows variants 16, 17, and 18 exhibited IC<sub>50 </sub>values of 0.7, 0.6, 0.5 nM while variant 15 exhibited an IC<sub>50 </sub>value of 1.7 nM, all possessing significantly better binding to NKG2D, 27, 32-, 38- and 11-fold better, than WT NKG2DL, respectively, as well as substantially better than WED-MICA (Table 3).</p><p id="p-0078" num="0075">Table 3. Equilibrium and kinetic binding parameters for &#x3b1;1-&#x3b1;2 variants. IC<sub>50 </sub>values were derived from 4-parameter fits to the competition binding titrations (<figref idref="DRAWINGS">FIGS. <b>12</b>A and <b>12</b>B</figref>) and the kinetic binding parameters were derived from single exponential fits to the binding kinetics (<figref idref="DRAWINGS">FIGS. <b>13</b>A and <b>13</b>B</figref>). Equilibrium binding constants (K<sub>d</sub>) were derived from the kinetic binding parameters using the equation K<sub>d</sub>=k<sub>OFF</sub>/k<sub>ON</sub>.</p><p id="p-0079" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="91pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><tbody valign="top"><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Kinetic Binding</entry><entry/></row><row><entry/><entry/><entry>Parameters</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>&#x3b1;1-&#x3b1;2 Variant</entry><entry>IC<sub>50 </sub>(nM)</entry><entry>K<sub>ON </sub>(M<sup>&#x2212;1</sup> s<sup>&#x2212;1</sup>)</entry><entry>K<sub>OFF </sub>(s<sub>&#x2212;1</sub>)</entry><entry>K<sub>d </sub>(nM)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>WT</entry><entry>19.4</entry><entry>1.3 &#xd7; 10<sup>5</sup></entry><entry>1.8 &#xd7; 10<sup>&#x2212;3</sup></entry><entry>13.8</entry></row><row><entry>WED</entry><entry>4.4</entry><entry>2.9 &#xd7; 10<sup>5</sup></entry><entry>1.7 &#xd7; 10<sup>&#x2212;3</sup></entry><entry>5.9</entry></row><row><entry>15</entry><entry>1.7</entry><entry>0.7 &#xd7; 10<sup>5</sup></entry><entry>1.1 &#xd7; 10<sup>&#x2212;4</sup></entry><entry>1.5</entry></row><row><entry>16</entry><entry>0.7</entry><entry>2.0 &#xd7; 10<sup>5</sup></entry><entry>0.9 &#xd7; 10<sup>&#x2212;4</sup></entry><entry>0.5</entry></row><row><entry>17</entry><entry>0.6</entry><entry>2.0 &#xd7; 10<sup>5</sup></entry><entry>0.7 &#xd7; 10<sup>&#x2212;4</sup></entry><entry>0.4</entry></row><row><entry>18</entry><entry>0.5</entry><entry>2.3 &#xd7; 10<sup>5</sup></entry><entry>0.9 &#xd7; 10<sup>&#x2212;4</sup></entry><entry>0.4</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0080" num="0076">Importantly, the relative IC<sub>50 </sub>differences also translated to better binding to murine NKG2D-Fc (<figref idref="DRAWINGS">FIG. <b>13</b>B</figref>), and demonstrated the ability to improve binding of soluble, modified &#x3b1;1-&#x3b1;2 domains across human and non-human NKG2D receptors, an important property for preclinical drug development.</p><p id="p-0081" num="0077">In order to understand the kinetic basis for the altered affinities, both the on-rates and off-rates for the &#x3b1;1-&#x3b1;2 variant NKG2DLs binding to surface coated biotinylated human NKG2D were measured using biolayer interferometry (Octet) at 100 nM of each of the modified &#x3b1;1-&#x3b1;2 proteins. Consistent with results from the IC<sub>50 </sub>ELISAs, variants 16, 17 and 18 each displayed significant reductions in the off-rate (18-fold relative to WT), which is largely responsible for the affinity increase (-30-fold relative to WT &#x3b1;1-&#x3b1;2)(<figref idref="DRAWINGS">FIG. <b>14</b></figref>; Table 3). Although variant 15 displayed a similar slow off-rate as did 16, 17, and 18, its on-rate was decreased, resulting in an affinity stronger than WT but weaker variants 16, 17 and 18. Because the only difference between variant 15 (SEQ ID NO.:31) and 16 (SEQ ID NO.:32) was K125N versus K125L, the mutation at position 125 clearly altered the on-rate while the decreased off-rate was attributed to the H161R mutation. Therefore, while the selected set of NKG2DL mutations (Table 1) was used to increase the &#x3b1;1-&#x3b1;2 affinity for NKG2D through significant off-rate reduction, certain substitutions also altered the on-rate resulting in a range of incremental affinity increases that we showed in this invention to have differential activity in the NK cell-mediated killing assays as described below.</p><p id="p-0082" num="0078">The ability of the &#x3b1;1-&#x3b1;2 affinity variants to redirect NK cell-mediated lysis of FGFR3-expressing target cells was demonstrated in vitro in a calcein-release assay. The human Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded P815 target cells ectopically expressing FGFR3 and titrated with soluble modified MIC proteins. The results in <figref idref="DRAWINGS">FIG. <b>15</b></figref> showed that the killing activities of the FGFR3-specific soluble MIC variants correlated with their engineered &#x3b1;1-&#x3b1;2 affinities. Specifically, variants 16, 17, and 18 exhibited &#x2dc;15-fold more killing than WT at 0.78 nM. The WED-MICA (SEQ ID NO.:35) was only slightly better than WT. Therefore, the invention describes amino acid substitutions within the &#x3b1;1-&#x3b1;2 domain that increased the NKG2D binding affinity by reducing the off-rate of soluble MIC protein binding to human NKG2D and consequentially led to the predictably increased killing potency. WED-MICA, which exhibited somewhat greater affinity than WT MICA to NKG2D (<figref idref="DRAWINGS">FIG. <b>13</b>A</figref>) by increasing on-rate rather than reducing off-rate (<figref idref="DRAWINGS">FIG. <b>14</b></figref>), did not exhibit substantial improvement of target cell killing (<figref idref="DRAWINGS">FIG. <b>15</b></figref>). Furthermore, as shown in <figref idref="DRAWINGS">FIG. <b>13</b>B</figref>, WED-MICA exhibited substantially poorer binding to murine NKG2D than even WT MICA, while variants 15, 16, 17, and 18 each exhibited greater affinity for both human and murine NKG2D, <figref idref="DRAWINGS">FIGS. <b>13</b>A and <b>13</b>B</figref>.</p><p id="p-0083" num="0079">These &#x3b1;1-&#x3b1;2 NKG2DL affinity variants 15, 16, 17, and 18 enhanced the binding affinity of the attached polypeptide to the NKG2D receptor and thereby enhanced NK cell-mediated lysis of targeted cells, <figref idref="DRAWINGS">FIG. <b>15</b></figref>.</p><p id="p-0084" num="0080">Example 4 (Modified &#x3b1;1-&#x3b1;2 Domains of NKG2D Ligands). This embodiment of the instant invention relates to additional &#x3b1;1-&#x3b1;2 NKG2DL affinity variants derived through engineering specific mutations at selected amino acid positions within the &#x3b1;1-&#x3b1;2 domain of soluble MIC molecules, as described in Example 3 (Table 1), that also influence the off-rate binding kinetics and thereby alter the NK cell-mediated killing activity of the non-natural &#x3b1;1-&#x3b1;2 domains. While variants 15-18 focused on specific mutations found at positions S20, G68, K125, and H161, another set of variants were isolated with additional mutations at E152, H158, and Q166 (Table 4).</p><p id="p-0085" num="0081">Table 4. Sequences of specific &#x3b1;1-&#x3b1;2 domain variants. The specific amino acid substitutions for variants 20, 25, and 48 are listed relative to the amino acids of SEQ ID NO.:35, shown in bold in the first row of the table. All amino acids are represented by the single letter IUPAC abbreviations.</p><p id="p-0086" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="9"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="21pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="21pt" align="center"/><colspec colname="9" colwidth="28pt" align="center"/><thead><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row><row><entry/><entry>SEQ</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>Variant</entry><entry>ID NO.:</entry><entry>S20</entry><entry>G68</entry><entry>K125</entry><entry>E152</entry><entry>H158</entry><entry>H161</entry><entry>Q166</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>20</entry><entry>39</entry><entry>S</entry><entry>A</entry><entry>L</entry><entry>Q</entry><entry>R</entry><entry>H</entry><entry>F</entry></row><row><entry>25</entry><entry>40</entry><entry>S</entry><entry>G</entry><entry>L</entry><entry>E</entry><entry>H</entry><entry>R</entry><entry>S</entry></row><row><entry>48</entry><entry>41</entry><entry>S</entry><entry>G</entry><entry>L</entry><entry>A</entry><entry>I</entry><entry>R</entry><entry>A</entry></row><row><entry namest="1" nameend="9" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0087" num="0082">DNA polynucleotides (SEQ ID NOs. 36-38) encoding the &#x3b1;1-&#x3b1;2 domains of 3 representative variants 20, 25, 48 (SEQ ID NOs. 39-41, respectively) that contained different combinations of specific discovered mutations (Table 4), were synthesized. To the NKG2DLs in the above example, heterologous molecules, such as an FGFR3-binding polypeptide, were directly attached to each of these 3 modified &#x3b1;1-&#x3b1;2 NKG2DLs using a linker peptide. The constructs were cloned into the Xbal and BamHI sites of pD2509, a CMV-based mammalian cell expression vector. Three His-tagged proteins (SEQ ID NOs.: 39-41), consisting of modified NKG2DLs with attached heterologous molecules that bind to FGFR3, were transiently expressed in HEK293 cells using the Expi293 expression system according to the manufacturer's protocol (Life Technologies), and purified using Ni-affinity chromatography to obtain the isolated proteins for biochemical and activity-based analysis.</p><p id="p-0088" num="0083">In order to characterize the NKG2D binding affinities, both the on-rates and off-rates for the three &#x3b1;1-&#x3b1;2 variant NKG2DLs binding to surface-coated biotinylated human NKG2D were measured using biolayer interferometry (Octet). Binding titrations were performed for each protein using a titration range of 1-100 nM, and the kinetic data were fitted to obtain on-rates, off-rates, and equilibrium binding constants.</p><p id="p-0089" num="0084">Variant 25 (SEQ ID NO.: 40) contains only the addition of the Q166S mutation relative to variant 16 (SEQ ID NO.: 32) (Table 2), and exhibited a NKG2D binding affinity of 62 pM largely due to decreased off-rate (<figref idref="DRAWINGS">FIG. <b>16</b></figref> and Table 5). This represented an 8-fold enhancement in equilibrium binding affinity due to the Q166S mutation (compare Table 3 and Table 5), and demonstrated that specific mutations at Q166 influenced binding affinity through decreased off-rate.</p><p id="p-0090" num="0085">Table 5. Kinetic binding parameters for &#x3b1;1-&#x3b1;2 variants. Kinetic binding parameters were derived from single exponential fits to the binding kinetics (<figref idref="DRAWINGS">FIG. <b>16</b></figref>). Equilibrium binding constants (K<sub>d</sub>) were derived from the kinetic binding parameters using the equation K<sub>d</sub>=k<sub>OFF</sub>/k<sub>ON</sub>.</p><p id="p-0091" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="105pt" align="center"/><colspec colname="3" colwidth="42pt" align="left"/><tbody valign="top"><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Kinetic Binding</entry><entry/></row><row><entry/><entry/><entry>Parameters</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="56pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><tbody valign="top"><row><entry/><entry>&#x3b1;1-&#x3b1;2 Variant</entry><entry>K<sub>ON </sub>(M<sup>&#x2212;1</sup> s<sup>&#x2212;1</sup>)</entry><entry>K<sub>OFF </sub>(s<sub>&#x2212;1</sub>)</entry><entry>K<sub>d </sub>(nM)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>20</entry><entry>3.6 x 105</entry><entry>3.0 x 105</entry><entry>0.083</entry></row><row><entry/><entry>25</entry><entry>4.7 x 105</entry><entry>2.9x105</entry><entry>0.062</entry></row><row><entry/><entry>48</entry><entry>2.0 x 105</entry><entry>3.0 x 1033</entry><entry>15</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0092" num="0086">Variant 20 (SEQ ID NO.: 39) contained the specific mutations G68A, E152Q, H158R and Q166F, and maintained binding parameters similar to variant 25 (Table 5), suggesting that this unique combination of specific mutations also has improved NKG2D binding affinity due to a decreased off-rate.</p><p id="p-0093" num="0087">Variant 48 (SEQ ID NO.: 41) contained the K125L and H161R mutations found in variant 16 (Table 2); however the addition of mutations E152A, H1581, and Q166A (Table 4) significantly increased the off-rate, resulting in a 250-fold reduction in NKG2D binding affinity (<figref idref="DRAWINGS">FIG. <b>16</b></figref> and Table 5). The Q166A mutation is not one of the favored affinity enhancement mutations selected for position Q166 (Table 1) and may have contributed to the reduction in off-rate observed. These data clearly demonstrated that unique combinations of engineered, mutations selected and identified at defined positions within &#x3b1;1-&#x3b1;2 domains tuned the NKG2D binding affinity through off-rate modulation.</p><p id="p-0094" num="0088">The non-natural &#x3b1;1-&#x3b1;2 affinity variants with attached polypeptides redirected NK cell-mediated lysis of FGFR3-expressing target cells, as demonstrated in vitro in a calcein-release assay. The human Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded P815 target cells ectopically expressing FGFR3, and titrated with soluble modified NKG2D ligand &#x3b1;1-&#x3b1;2 proteins. The results in <figref idref="DRAWINGS">FIG. <b>17</b></figref> showed that the killing potencies of the FGFR3-targeted soluble MIC variants correlated with their engineered &#x3b1;1-&#x3b1;2 affinities. Specifically, variant 25 exhibited &#x2dc;3-fold greater killing than variant 16 at 0.2 nM, representing an &#x2dc;5-fold improvement in the EC50 for cell killing. In addition, the data clearly showed preferred killing activity across representative soluble MIC variants in the order of variant 25&#x3e;16&#x3e;WED (<figref idref="DRAWINGS">FIG. <b>17</b></figref>).</p><p id="p-0095" num="0089">Example 5 (Modified &#x3b1;<b>1</b>-&#x3b1;<b>2</b> Domains of NKG2D Ligands). This embodiment relates to additional &#x3b1;1-&#x3b1;2 NKG2DL affinity variants derived through engineering the &#x3b1;1-&#x3b1;2 domains of ULBP proteins. ULBP proteins contain &#x3b1;1-&#x3b1;2 domains, which are NKG2D ligands capable of binding to the NKG2D receptor (Cerwenka A, Lanier L L (2004). NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. <i>Tissue Antigens </i>61 (5): 335-43. doi:10.1034/j.1399-0039.2003.00070.x. PMID 12753652). This affinity of NKG2D binding is sufficient for physiologic activation of NK cells and stimulating lysis of cells expressing native full-length ULBP proteins naturally and irreversibly tethered to the two-dimensional plasma membrane surface of a &#x201c;target cell&#x201d; (Cerwenka A, Lanier LL (2004). NKG2D ligands: unconventional WIC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61 (5): 335-43. doi:10.1034/j.1399-0039.2003.00070.x. PMID 12753652). However, because engineered soluble &#x3b1;1-&#x3b1;2 domains fused to heterologous polypeptides in certain embodiments of the instant invention reversibly bind specific target antigens on the surface of a target cell, the binding affinity of the engineered ULBP &#x3b1;1-&#x3b1;2 domains to NKG2D will directly affect the stability of the artificial synapse formed between NK cells and cells expressing target antigens, as already shown by engineered soluble MIC proteins (Examples 2-4). In order to diversify the repertoire of engineered non-natural &#x3b1;1-&#x3b1;2 domains as NKG2D ligands, ULBP proteins were used as a substrate or starting point for phage display-based engineering of their NKG2D binding affinity. Despite the structural homology observed between ULBPs and MICA (Radaev, S., Rostro, B., Brooks, A G., Colonna, M., Sun, P D. (2001) Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like Ligand ULBP3. <i>Immunity </i>15, 1039-49.), the sequence homology is &#x3c;50% for the ULBP &#x3b1;1-&#x3b1;2 domains relative to MICA (<figref idref="DRAWINGS">FIG. <b>18</b></figref>). Thus, we sought the identities of codon positions in ULBP &#x3b1;1-&#x3b1;2 domains that improve NKG2D binding affinity.</p><p id="p-0096" num="0090">To engineer soluble, non-natural &#x3b1;1-&#x3b1;2 domains from ULBP proteins, ULBP2 and ULBP3 were chosen for phage display and selection of mutants with high affinity NKG2D binding. Sixty amino acid positions in the &#x3b1;1-&#x3b1;2 domain of ULBP2 (SEQ ID NO.:16), and thirty-six amino acid positions in the &#x3b1;1-&#x3b1;2 domain of ULBP3 (SEQ ID NO.: 17), were chosen for extensive mutagenesis (<figref idref="DRAWINGS">FIG. <b>18</b></figref>). In addition, conservative cysteine-to-serine mutations were made at C8S in ULBP2 (SEQ ID NO.:16) and C103S in ULBP3 (SEQ ID NO.: 17) in order to remove unpaired free cysteines that could interfere with phage panning. Synthetic DNA libraries coding for these &#x3b1;1-&#x3b1;2 domains, and containing NNK mutagenic codons at each of the selected amino acid positions, were synthesized, individually; cloned as fusions to the pIII minor coat protein of M13 phage; and phage particles displaying the mutagenized &#x3b1;1-&#x3b1;2 ULBP2 or ULBP3 variants were produced in SS320 E.coli cells according to standard methodologies (Andris-Widhopf, J., Steinberger, P., Fuller, R., Rader, C., and Barbas, C. F., 3rd. (2011). Generation of human Fab antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences, <i>Cold Spring Harbor protocols </i>2011). The &#x3b1;1-&#x3b1;2 phage display libraries were sorted for increased binding affinity to NKG2D using human NKG2D-Fc as the target protein, and cycled through iterative rounds of intentionally prolonged binding, prolonged washing, and eluting of the phage clones in order to select high affinity variants enriched for slow dissociation- or off-rates. For ULBP2, specific amino acid mutations were found at high frequencies at positions R80, V151, V152, and A153 in &#x3b1;1-&#x3b1;2, and were identified as preferred amino acid substitutions with enhanced NKG2D-binding affinity (<figref idref="DRAWINGS">FIG. <b>19</b>A</figref> and Table 6).</p><p id="p-0097" num="0091">Table 6. Selected affinity mutations at the indicated 4 amino acid positions of the &#x3b1;1-&#x3b1;2 domain of ULBP2. The amino acids of SEQ ID NOs.:16 at each of the 4 positions are shown in bold in the first row of the table. The identified affinity mutations are listed in decreasing frequency from top to bottom. All amino acids are represented by the single letter IUPAC abbreviations.</p><p id="p-0098" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>R80</entry><entry>V151</entry><entry>V152</entry><entry>A153</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>L</entry><entry>D</entry><entry>L</entry><entry>E</entry></row><row><entry/><entry>W</entry><entry>E</entry><entry>W</entry><entry>K</entry></row><row><entry/><entry>V</entry><entry>Q</entry><entry/><entry>G</entry></row><row><entry/><entry>F</entry><entry>K</entry><entry/><entry>P</entry></row><row><entry/><entry>I</entry><entry>N</entry><entry/><entry/></row><row><entry/><entry>S</entry><entry>R</entry><entry/><entry/></row><row><entry/><entry>A</entry><entry>T</entry><entry/><entry/></row><row><entry/><entry>E</entry><entry/><entry/><entry/></row><row><entry/><entry>P</entry><entry/><entry/><entry/></row><row><entry/><entry>T</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0099" num="0092">For ULBP3, specific amino acid mutations were found at high frequencies in different locations relative to ULBP2 (<figref idref="DRAWINGS">FIG. <b>18</b></figref>). Positions R162 and K165 in the &#x3b1;1-&#x3b1;2 domain of ULBP3 contained specific mutations that were identified as preferred amino acid substitutions with enhanced NKG2D-binding affinity (<figref idref="DRAWINGS">FIG. <b>19</b></figref> B and Table 7). These modified non-natural &#x3b1;1-&#x3b1;2 domains derived from ULBP2 and ULBP3 can be used for enhanced NKG2D binding in multiple therapeutic formats as single proteins or fusions to heterologous peptides or polypeptides.</p><p id="p-0100" num="0093">Table 7. Selected affinity mutations at the indicated 2 amino acid positions of the &#x3b1;1-&#x3b1;2 domain of ULBP3. The amino acids of SEQ ID NOs.:17 at each of the 2 positions are shown in bold in the first row of the table. The identified affinity mutations are listed in decreasing frequency from top to bottom. All amino acids are represented by the single letter IUPAC abbreviations.</p><p id="p-0101" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="63pt" align="left"/><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>R162</entry><entry>K165</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>G</entry><entry>S</entry></row><row><entry/><entry>A</entry><entry>P</entry></row><row><entry/><entry>Y</entry><entry>A</entry></row><row><entry/><entry/><entry>T</entry></row><row><entry/><entry/><entry>H</entry></row><row><entry/><entry/><entry>N</entry></row><row><entry/><entry/><entry>Q</entry></row><row><entry/><entry/><entry>G</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0102" num="0094">Example 6 (Modified &#x3b1;1-&#x3b1;2 Domains fused to antibody peptides). These are examples of attaching antibody polypeptides to NKG2DLs which were modified to significantly enhance their binding affinity to the human NKG2D receptor. The &#x3b1;1-&#x3b1;2 domain of MIC proteins is an NKG2DL for the NKG2D receptor. Antibodies are highly stable glycoproteins made up of two large heavy chains and two small light chains (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). The large amount of diversity that can be generated within the CDR regions of the variable domains allows for specific antibodies to be generated to specific antigen targets (Hozumi N, Tonegawa S (1976). &#x201c;Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions&#x201d;. <i>Proc. Natl. Acad. Sci. U.S.A. </i>73 (10): 3628-3632. doi:10.1073/pnas.73.10.3628. PMC 431171. PMID 824647.) Antibodies have become a significant therapeutic platform for drug development and can mediate both target binding and neutralization, as well as modulate the immune system through complement and Fc receptor binding (Vidarsson, G., Dekkers, G., Rispens, T. (2014) IgG subclasses and allotypes: from structure to effector functions. <i>Frontiers in Immunology </i>5, 520.). Prior to the present invention, there did not exist an IgG antibody format that can directly activate immune cells using non-natural &#x3b1;1-&#x3b1;2 domains that bind more tightly than native NKG2DLs to the NKG2D receptor. Previous work has demonstrated that the mouse NKG2D ligand, Rael beta, can be fused to an anti-Her2 antibody for use as an anti-tumor agent in mice (Cho, H M., Rosenblatt, J D., Tolba, K., Shin, S J., Shin, D., Calfa, C., Zhang, Y., Shin, S U. (2010) Delivery of NKG2D ligand using and anti-Her2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Research 70, 10121-30.). However, mouse NKG2D ligands do not bind human NKG2D, and there are no natural human NKG2D ligands with high affinity to human and mouse NKG2D. Fusions between the engineered &#x3b1;1-&#x3b1;2 NKG2D ligands of the instant invention and the heavy chain or light chain of IgG antibodies (<figref idref="DRAWINGS">FIGS. <b>20</b>A and <b>20</b>B</figref>) overcame these limitations and highlighted the versatility of fusions of modified &#x3b1;1-&#x3b1;2 domains to heterologous proteins or peptides.</p><p id="p-0103" num="0095">To generate variant &#x3b1;1-&#x3b1;2 domain fusions to antibodies, the DNA sequences encoding &#x3b1;1-&#x3b1;2 domain for MIC WT, variants WED, 25, and 48, were synthesized and cloned as C-terminal fusions to either the heavy chain (HC_WT, HC_WED, HC_25, HC_48) or light chain (LC_WT, LC_WED, LC_25, LC_48) sequence from the FGFR3-specific antibody (Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., Ross, S., Stinson, S., Dornan, D., French, D., Wang, Q. R., Stephan, J. P., Wu, Y., Wiesmann, C., and Ashkenazi, A. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice, <i>The Journal of clinical investigation </i>119, 1216-1229.) (SEQ ID NOs.: 42-49, respectively). The resulting fusions were cloned into the mammalian expression vector pD2509 and expressed as paired full IgG antibodies with either heavy or light chain fusions of the modified &#x3b1;1-&#x3b1;2 domains (SEQ ID NOs.: 50-57, respectively). Transient expressions were carried out in HEK293 cells using the Expi293 expression system according to the manufacturer's protocol (Life Technologies), and purified using standard protein A affinity chromatography. The ability of the non-natural &#x3b1;1-&#x3b1;2-antibody fusions to redirect NK cell-mediated lysis of FGFR3-expressing target cells was demonstrated in vitro in a calcein-release assay. The human Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded P815 target cells ectopically expressing FGFR3 and titrated with the engineered antibody fusion proteins. The results in <figref idref="DRAWINGS">FIGS. <b>20</b>C and <b>20</b>D</figref> showed that the killing activities of the FGFR3-specific non-natural &#x3b1;1-&#x3b1;2-antibody fusions correlated with their engineered NKG2D affinities. Specifically, antibodies that contained either heavy chain or light chain fusions of non-natural variants 25 and 48 (HC_25, HC_48 and LC_25, LC_48) killed FGFR3-expressing cells more effectively than antibody fusions containing either WT or WED &#x3b1;1-&#x3b1;2 domains.</p><p id="p-0104" num="0096">This was further demonstrated to be a general and useful approach to fusing modified &#x3b1;1-&#x3b1;2 domains to antibodies, by fusing the variant 25 &#x3b1;1-&#x3b1;2 domain to the C-terminal of either the heavy chain or light chain of EGFR-specific antibody cetuximab (U.S. Pat. No. 6,217,866), Her2-specific antibody trastuzumab (Carter, P., Presta, L., Gorman, CM., Ridgway, JB., Henner, D., Wong, WL., Rowland, AM., Kotts, C., Carver, ME., Shepard, HM. (1992) Proc Natl Acad Sci 15, 4285-9), or an anti-PDL1 antibody (US Patent 20140341917) (SEQ ID NOs.:58-63, respectively). The resulting fusions were expressed as paired light and heavy chain full IgG antibodies with either heavy or light chain fusions of the variant 25 &#x3b1;1-&#x3b1;2 domain. Transient expressions were carried out in HEK293 cells using the Expi293 expression system according to the manufacturer's protocol (Life Technologies), and purified using standard protein A affinity chromatography. The ability of the variant 25 antibody fusions to redirect NK cell-mediated lysis of target-expressing cells was demonstrated in vitro in a calcein-release assay. The human Natural Killer (NK) cell line, NKL, was co-cultured with calcein-loaded A431 EGFR-expressing target cells, SKBR3 Her2-expressing target cells, or PDL1-expressing B16 cells and titrated with the respective target-specific engineered antibody fusion proteins. The results in <figref idref="DRAWINGS">FIGS. <b>21</b>A, <b>21</b>B, and <b>21</b>C</figref> showed that the killing activities of the target-specific variant 25-antibody fusions were in all cases drastically improved over the non-fused parent antibody and very potent with sub-nanomolar EC50 values. These data show that modified &#x3b1;1-&#x3b1;2 variant-antibody fusions are a universal platform for allowing IgG antibodies to bind tightly to NKG2D and to direct antigen-specific cell lysis.</p><p id="p-0105" num="0097">Example 7 (trastuzumab fusions to &#x3b1;1-&#x3b1;2 variant 25 bind NK cells in vivo and elicit potent antigen presentation). Fusion proteins containing &#x3b1;1-&#x3b1;2 domain variants that bind NKG2D with high affinity bound NK cells in vivo. Thus, antigen-specific antibodies containing modified &#x3b1;1-&#x3b1;2 fusions bind NKG2D tightly and thereby effectively armed the surface of NK cells in vivo with antibodies to seek out target cells expressing a particular antigen. This activity was similar to engineered CAR cells (Gill, S., and June, C H. (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263, 68-89.), but did not require genetic modification of the NKG2D-expressing cell type.</p><p id="p-0106" num="0098">To demonstrate that antibodies containing modified &#x3b1;1-&#x3b1;2 fusions bind NK cells in vivo, trastuzumab and the corresponding heavy and light chain fusions of variant 25 were analyzed in vivo for serum pharmacokinetic (PK) profiles and the pharmacodynamics (PD) of NK cell labeling. All three antibodies: parent trastuzumab; trastuzumab HC_25 fusion; and trastuzumab LC_25 fusion, were conjugated with Alexa Flour 647 according to the manufacturer's protocol (Life Technologies). Groups of three C57BL/6 mice were injected with a single dose of 100 &#x3bc;g of each antibody, and blood was drawn at indicated time points for plasma PK ELISAs and flow cytometry of peripheral NK cells. The PK profile of the parent trastuzumab antibody displayed typical alpha-phase distribution within 24-hrs and beta-phase elimination consistent with greater than a 1 week half-life of antibodies in mice (<figref idref="DRAWINGS">FIG. <b>22</b>A</figref>). For both the heavy chain and light chain fusions with variant 25, the initial alpha-phase showed a much greater volume of distribution relative to the parent antibody, consistent with an NKG2D-sink, while the beta-phase elimination was also consistent with typical antibody clearance in mice (<figref idref="DRAWINGS">FIG. <b>22</b>A</figref>). Using flow cytometry of peripheral NK cells from the mouse blood, the level of NK cell staining with Alexa Fluor 647 showed a clear time-dependent increase in the percent of NK cells labeled with the antibody fusion, but not the parent antibody (<figref idref="DRAWINGS">FIG. <b>22</b></figref> B). The increase in labeling by the fusions peaked within 24 hrs, consistent with the sink observed in the PK profiles for the fusions, and was stable at least for three days post injection. The combined PK and PD data demonstrate that the trastuzumab antibodies containing variant 25 &#x3b1;1-&#x3b1;2 fusions formed stable complexes with NKG2D on NK cells in vivo.</p><p id="p-0107" num="0099">To assess the appearance of anti-drug antibodies (ADAs) to the human IgG trastuzumab antibody, the plasma samples from the PK/PD study were assessed for ADAs using an ELISA. In <figref idref="DRAWINGS">FIGS. <b>23</b>A-C</figref>, ELISAs for mouse IgG binding to wells coated with the 3 respective dosed antibodies revealed that only the antibodies fused with variant 25 elicited ADAs within seven days after a single dose of antibody. The parent trastuzumab antibody gave no ADA signal. In order to determine whether the antibody fusions elicited an immune (ADA) response to both the &#x3b1;1-&#x3b1;2 domain and the antibody (trastuzumab) component when the trastuzumab antibody itself did not elicit an immune response, the ADA-positive plasma from the antibody fusions were tested against the parent antibody and the variant 25 &#x3b1;1-&#x3b1;2 domain individually; both moieties reacted with ADAs from plasma (<figref idref="DRAWINGS">FIGS. <b>24</b>A and <b>24</b>B</figref>). These data demonstrate that the fusion of high affinity variant 25 to the parent antibody mediated NKG2D-dependent uptake and antigen presentation to elicit potent and rapid immune responses to the parent antibody, which alone was not so immunogenic in mice. Thus, a high affinity variant &#x3b1;<b>1</b>-&#x3b1;2 domain attached to an antigen or immunogen provided potent presentation of the antigen and epitope spreading, effectively serving as a potent adjuvant for immunization.</p><p id="p-0108" num="0100">The demonstrated combined effects of arming circulating NK cells for directed target cell lysis and enhancing antigen presentation are important activities for antibody fusions to modified &#x3b1;1-&#x3b1;2 domains that can provide therapeutic benefit.</p><p id="p-0109" num="0101">Example 8 (Antibody heavy chain fusion to &#x3b1;1-&#x3b1;2 variant 25 exhibited anti-tumor activity in vivo). To examine the potential for antigen-specific antibodies fused to modified &#x3b1;1-&#x3b1;2 to have anti-target cell activity, an anti-PDL1 antibody heavy chain fusion to variant 25 &#x3b1;1-&#x3b1;2 was evaluated in a syngeneic MC38 tumor model. MC38 tumors were implanted sub-cutaneously in C57BL/6 mice and tumors grew to an average of 100 mm<sup>3 </sup>before the initiation of treatment. Upon initiation of treatment, four cohorts of 10 mice per group were treated with vehicle, anti-CTLA4 (100 ug i.p.), parent anti-PDL1 (300 ug i.v.), or anti-PDL1 HC<sub>&#x2dc;</sub>25 fusion (300 ug i.v.) on days 1, 4, and 7. In <figref idref="DRAWINGS">FIG. <b>25</b></figref>, the tumor growth curves showed that anti-PDL1 HC<sub>&#x2dc;</sub>25 mediated the most effective anti-tumor activity within the first two weeks of treatment. Tumor growth inhibition was significantly better than the established anti-CTLA4 treatment and the parent anti-PDL1 antibody over the first 12 days after initiation of treatment. By day 16, the anti-PDL1 HC_25 treatment began to lose efficacy consistent with the occurrence of an ADA response as observed for trastuzumab fusions (Example 7). The significant anti-tumor activity observed for the antibody heavy chain fusion to variant 25 relative to both the parent antibody and standard anti-CTLA4 treatments demonstrated the impressive therapeutic effect of antibody fusions to modified &#x3b1;1-&#x3b1;2 domains that served as high affinity NKG2D ligands.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002475A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.26"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An insertable Fv (iFv) polypeptide exhibiting specific antigen-binding properties comprising a variable fragment (Fv) of an antibody, wherein the specific antigen-binding domain of the Fv comprises two antibody variable domains, one variable domain from the light chain (VL) and one variable domain from the heavy chain (VH), each with 1-3 complementarity determining regions (CDRs), and each with a C-terminus and an N-terminus; and wherein the VL and VH domains are joined by two linker regions connecting both canonical termini of the VL domain to both canonical termini of the VH domain.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The iFv of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein a non-natural pair of N- and C-termini have been created within either the VL or the VH domain to provide an attachment site for conjugation to or insertion into a recipient molecule.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The iFv of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the non-natural N- and C-termini are spatially positioned proximal to each other.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The iFv of <claim-ref idref="CLM-00002">claim 2</claim-ref>, further comprising a recipient polypeptide or protein containing one or more solvent exposed loops, wherein the iFv is inserted into one or more of the loops.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The iFv of <claim-ref idref="CLM-00002">claim 2</claim-ref>, further comprising a recipient polypeptide or protein containing one or more solvent exposed loops, wherein the iFv is inserted into one or more of the loops, such that the non-natural N- and C-termini within the VL or VH domains are spatially positioned proximal to each other.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The iFv of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein either the C-terminus of the VL domain is connected to the N-terminus of the VH domain and the N-terminus of the VL domain is connected to the C-terminus of the VH domain; or wherein the N-terminus of the VL domain is connected to the C-terminus of the VH domain and the C-terminus of the VL domain is connected to the N-terminus of the VH domain.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The iFv of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the distance between the non-natural N- and C-termini is between about 0.2 and about 2.0 nm.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The iFv of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the distance between the termini is between about 0.5 nm and about 1.5 nm.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The iFv of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the two linker regions comprise identical or non-identical peptides of about 10 to 25 amino acids.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The iFv of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the recipient polypeptide or protein is an antibody, Ig fold, Ig domain, globulin, albumen, fibronectin, fibronectin domain, integrin, fluorescent protein, enzyme, outer membrane protein, receptor protein, T-cell receptor, chimeric antigen receptor, viral antigen, virus capsid, viral ligand for cell receptor, high molecular weight bacteriocin, histone, hormone, knottin, cyclic peptide, ULB protein, lectin, or a ligand for a lectin.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The iFv of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a non-protein molecule to which the iFv is inserted into, or attached.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The iFv of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the non-protein molecule is a polysaccharide, dendrimer, polyglycol, peptidoglycan, chemotherapeutic agent, toxin, fluorophore, chromophore, pharmacophore, antibiotic or polyketide.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The iFv of <claim-ref idref="CLM-00002">claim 2</claim-ref>, further comprising a non-protein molecule or an atom conjugated to one or both of the non-natural N-terminus and the non-natural C-terminus.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The iFv of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein all or a portion of the one or more solvent-exposed loops of the recipient molecule is deleted and replaced with the iFv.</claim-text></claim></claims></us-patent-application>